EP1385472A2 - Filtering suntan product - Google Patents

Filtering suntan product

Info

Publication number
EP1385472A2
EP1385472A2 EP02726261A EP02726261A EP1385472A2 EP 1385472 A2 EP1385472 A2 EP 1385472A2 EP 02726261 A EP02726261 A EP 02726261A EP 02726261 A EP02726261 A EP 02726261A EP 1385472 A2 EP1385472 A2 EP 1385472A2
Authority
EP
European Patent Office
Prior art keywords
composition
agent
product according
ultraviolet radiation
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02726261A
Other languages
German (de)
French (fr)
Inventor
Rainer Schmidt
Marcelle Regnier
Christine Duval
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Publication of EP1385472A2 publication Critical patent/EP1385472A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/04Preparations for care of the skin for chemically tanning the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Definitions

  • the subject of the invention is a product comprising at least one agent which filters ultraviolet radiation and at least one compound which stimulates the synthesis of. melanin, a composition comprising at least said product, the use of said product in a composition or for the preparation of a composition intended to protect the skin from the harmful action of ultraviolet radiation, as well as a method of cosmetic treatment of the skin.
  • Solar radiation is composed, among other things, of type A ultraviolet radiation of wavelengths between 320 nm and 400 nm (UV-A), of type B ultraviolet radiation of wavelengths between 280 and 320 nm (UV-B) and type C ultraviolet radiation of wavelengths between 200 and 280 nm (UV-C).
  • UV-A type A ultraviolet radiation of wavelengths between 320 nm and 400 nm
  • UV-B type B ultraviolet radiation of wavelengths between 280 and 320 nm
  • UV-C type C ultraviolet radiation of wavelengths between 200 and 280 nm
  • UV-B are highly energetic and not very penetrating, poorly represented in sunlight, dependent on climatic variations (cloudy weather, overcast, etc.) and their presence varies according to the hours of the day (notion of peak (zenith)) .
  • UV-A is less energetic than UV-B but more penetrating, present in large quantities in sunlight (at least 100 times more UV-A than UV-B), little dependent on climatic variations and present whatever time of day.
  • UV-C is highly energetic and not very penetrating. They are stopped by the ozone layer and theoretically do not arrive on earth. But potentially they can be responsible for damage to nucleic acids.
  • browning commonly known as tanning
  • melanocytes in the basal layer of the epidemic synthesize melanin which, once incorporated into keratinocytes, constitutes a natural filter located on the surface of the skin, a filter which absorbs ultraviolet radiation.
  • melanin in the form of a particle, can also act as a UV-reflecting screen. This is intended to decrease the amount of ultraviolet radiation that passes through the layers of the skin in order to prevent it from reaching the deep layers and causing harmful damage to the skin.
  • UV-B mainly affects the epidermis.
  • Their main chromophore is nucleic acids, in particular deoxyribonucleic acid, within which they induce lesions and / or mutations (Eller MS, 1995, in Photodamage.
  • UV A rays which cross the epidermis and reach the dermis, are strongly involved in photoaging of the skin: they contribute for example to the appearance of solar elastosis. Furthermore, it is known that photosensitization reactions and photodermatoses such as polymorphic dermatitis are mediated mainly by UVA.
  • UVA is also mutagenic (Stary A. Mutation Res. 1997; 398: 1-8) and photocarcinogenic (De Laat A., 1998, in Protection of the skin against ultraviolet radiations. 19-23, John Libbey Eurotext ed) and in addition with UVB, can contribute to the development of skin cancer.
  • UVA alters the melanocyte and cause the appearance of pigmentation spots (lentîgo) and the increase in risk of developing melanoma (R ⁇ ngerTM Photodermatol. Photoimmunol. Photmed. 1999; 15-212-216)
  • compositions comprising a filtering agent having an average protection index allowing both a certain protection and a certain browning.
  • the filtering agent is in high quantity, it will all the more limit the stimulation by the ultraviolet rays of the synthesis of melanin by the melanocytes.
  • a composition containing a small or medium amount of filtering agent does not have sufficient guarantees in terms of protection against the harmful effects of ultraviolet radiation, nor does it provide sufficient satisfaction in terms of obtaining browning.
  • certain associations have been proposed to reinforce the browning of the skin, with a sunscreen.
  • compositions containing psoralen derivatives and a filtering agent have thus been described in FR 2409751 or FR 2797585.
  • psoralen derivatives such as 5-methoxy psoralen require simultaneous irradiation of the skin with doses of 'UVA, which can damage DNA; in addition, the use of such psoralen derivatives is not desirable since they could be involved in photosensitization reactions.
  • Combinations of UV filters with tyrosine or xanthines have also been proposed, in particular in FR 2 624 374 or FR 2 607 699; however, the activity of these preparations has not been demonstrated, and they also require significant irradiation of the skin, and often additional adjuvants.
  • CH 642357 describes compositions containing tyrosine derivatives of UV filters and chromophoric derivatives.
  • WO 91/07945 or EP 380335 propose the use of xanthines to promote tanning, possibly associated with a sunscreen.
  • the efficacy of xanthines as a browning agent in humans is not satisfactory.
  • WO 98/25584 claims anti-inflammatory and activating melanogenesis compositions containing ⁇ MSH and SOD derivatives, to which titanium oxide can be added. It is known that derivatives of this hormone can have activities on various functions of the organism and in addition have a weak pro-pigmenting power.
  • the Applicant has now shown that the combination of an agent filtering ultraviolet radiation and a compound stimulating the synthesis of melanin has a surprising effect which leads to the production of a filtering and tanning product having filtering qualities. and a high stimulation capacity for the synthesis of meianin.
  • the primary object of the invention is therefore a product composed by at least the combination of at least one agent which filters ultraviolet radiation and one agent which stimulates the synthesis of melanin.
  • compositions solve the problem of obtaining browning and protection of the skin equivalent to that obtained after sun exposure without subjecting it to the risks induced by irradiation by UV radiation, in particular UVA rays.
  • the subject of the invention is also a composition comprising at least the combination of at least one agent which filters ultraviolet radiation and one agent which stimulates the synthesis of melanin.
  • the agent stimulating the synthesis of melanin is an agent which is not likely to cause systemic side effects on the organism, in particular hormonal, nor phenomena of photosensitization.
  • the ultraviolet radiation filtering agent is preferably chosen from organic filters and / or mineral filters.
  • organic filters mention may be made in particular of cinnamic derivatives, salicylic derivatives, camphor derivatives, triazine derivatives, benzophenone derivatives, dibenzoylmethane derivatives, ⁇ , ⁇ -diphenylacrylate derivatives, derivatives of p-aminobenzoic acid, the filter polymers and filter silicones described in application WO-93/04665 or also the organic filters described in patent application EP-A 0487404.
  • pigments or else nanopigments average size of the primary particles: generally between 5 nm and 100 nm, preferably between 10 and 50 nm
  • metallic oxides coated or not such as for example nanopigments of titanium oxide (amorphous or crystallized in rutile form and / or anatase), iron, zinc, zirconium or cerium which are all well known photoprotective agents acting by physical blocking (reflection and / or diffusion) of UV radiation.
  • Conventional coating agents are moreover alumina and / or aluminum stearate.
  • Such nanopigments of metallic oxides, coated or uncoated are in particular described in patent applications EP-A- 0 518 772 and EP-A- 0 518
  • Examples of active solar filters in UV-A and / or UV-B include:
  • the amount of compound recognized as a filtering agent for ultraviolet radiation, contained in the composition of the invention is of course a function of the desired effect and can therefore vary to a large extent.
  • the I P UVA UVA protection index
  • the I P UVA UVA protection index
  • JCIA Japonese Cosmetic Industry Association, Measurement standards for UVA efficacy. Tokyo, Japan: 1995
  • the filter preparation will have a sun protection factor or SPF (sun protection factor) determined according to the Colipa method (The European cosmetic toiletry and perfumery association (Colipa). Sun protection factor method. Report 94/289. Brussels Belgium, 1994) at least equal to 10 and less than or equal to 60, preferably from 15 to 30.
  • SPF sun protection factor
  • the filter preparation will thus contain a quantity of UVB and UVA filters so as to combine with a high SPF, an IP UVA also high.
  • Filters particularly suitable for the implementation of the invention will be chosen from the group comprising 2-ethylhexyl salicylate, 4-ter-butyl-4'-methoxy-dibenzoylmethane, 2-hydroxy-4-methoxybenzophenone-5 -sulfonate, benzene acid 1,4 ⁇ di (3-methylidene-10-camphosulfor ⁇ ique) and its salts, and mixtures of these compounds.
  • the quantity of filtering agents for ultraviolet radiation contained in the composition is in an amount representing from 0.1% to 25% of the total weight of the composition, in particular from 6 to 25%; advantageously it will be at least 8%, and preferably less than or equal to 15% of the total weight of the composition; according to another advantageous embodiment of the invention, the filtering agents are present in an amount representing from 0.5% to 10% of the total weight of the composition.
  • the agent (s) stimulating the synthesis of melanin can be chosen from:
  • activators of the activity or expression of tyrosinase such as forskolin, xanthic bases (theophylline, caffeine), pro-opiomelanocortic peptides (ACTH, alpha-MSH or other agonists of MC1 receptors), diacylglycerols, aliphatic or cyclic diols, psoralens, prostaglandins and the like, activators of protein kinase G NO / cGMP dependent, - activators of transfer of melanosomes to keratinocytes such as serine proteases or receptor agonists BY 2.
  • tyrosinase such as forskolin, xanthic bases (theophylline, caffeine), pro-opiomelanocortic peptides (ACTH, alpha-MSH or other agonists of MC1 receptors), diacylglycerols, aliphatic or cyclic diols, psoralen
  • an extract obtained from a plant in particular from Burnet (Sanguisorba officinalis), is used, or an extract from at least one plant of the genus Chrysanthemum, particularly of the species Chrysanthemum sinensis.
  • the extract of at least one plant of the genus Chrysanthemum can be any extract prepared from any plant material derived from a plant of the genus
  • the composition may contain at least one extract of at least one plant of the genus Chrysanthemum obtained from material obtained from a plant cultivated in vivo or derived from culture in vitro.
  • in vivo culture means any culture of the conventional type, that is to say in soil in the open air or in a greenhouse, or even above ground.
  • in vitro culture means all of the techniques known to those skilled in the art which artificially make it possible to obtain a plant or part of a plant.
  • an extract obtained from plant material cultivated in vivo is used, and even more preferably an extract obtained from leaves of plants of the genus Chrysanthemum cultivated in vivo.
  • extract of at least one plant of the genus Chrysanthemum is understood to mean both a crude mixture of parts of the plant roughly reduced to pieces and of the extraction solvent, as well as preparations prepared from the active principles dissolved during the extraction. It will be possible in particular to use extracts prepared according to the techniques described in application FR2 768343, which is incorporated here by reference.
  • a particularly usable extract according to the invention is produced by fine grinding of parts of the plant followed by maceration in the extraction solvent, said solvent preferably being a hydrophilic solvent, and finally by filtration.
  • the extract according to the invention can be each of the extracts thus obtained used alone or in admixture with one or more of the other extracts. Any extraction method known to a person skilled in the art can be used according to the invention.
  • aqueous, alcoholic, in particular ethanolic, extracts, hydroalcoholic extracts Mention may in particular be made of aqueous, alcoholic, in particular ethanolic, extracts, hydroalcoholic extracts.
  • the techniques used to obtain it are those generally described in the prior art and well known to those skilled in the art.
  • a first step the plant material is ground in a cold aqueous solution
  • the particles in suspension are removed from the aqueous solution obtained from the first step
  • the aqueous solution obtained from the second step is ground in a cold aqueous solution
  • This aqueous solution corresponds to the extract.
  • the first step can advantageously be replaced by a simple freezing operation of the plant tissues (for example at -20 ° C.), followed by an aqueous extraction repeating the second and third steps described above.
  • the extract which can be used according to the invention may undergo successive fractionation stages, with a view to concentrating the active principles.
  • this fractionation will be carried out by a liquid / liquid extraction, the fractions extracted by a hydroalcoholic mixture will preferably be used, eliminating the top fractions.
  • the extract obtained can be lyophilized by any conventional lyophilization method.
  • a powder is thus obtained which can be used directly or else mix in an appropriate solvent before use.
  • an aqueous extract is used.
  • Burnet extract use is preferably made, according to the invention, of a dry extract of the root and rhizome of Sanguisorba officinalis which can in particular be obtained in powder form from MARUZEN PHARMACEUTICALS CO., LTD (Burnet Extract Powder).
  • the amount of compound stimulating the synthesis of melanin contained in the composition of the invention is of course a function of the desired effect and can therefore vary to a large extent.
  • the compound stimulating the synthesis of melanin contained in the composition is in an amount representing from 0.01% to 15% of the total weight of the composition and preferably in an amount representing from 0.5% to 5% , in particular from 1 to 5% of the total weight of the composition.
  • compositions according to the invention may also contain artificial tanning and / or browning agents for the skin (self-tanning agents), such as for example dihydroxyacetone (DHA).
  • artificial tanning and / or browning agents for the skin such as for example dihydroxyacetone (DHA).
  • DHA dihydroxyacetone
  • compositions of the invention may also comprise conventional cosmetic adjuvants in particular chosen from fatty substances, organic solvents, thickeners, softeners, antioxidants, opacifiers, stabilizers, emollients, hydroxy acids, anti-aging agents. foam, moisturizing agents, vitamins, perfumes, preservatives, surfactants, fillers, sequestrants, propellants, alkalizing or acidifying agents, colorants, or any other ingredient usually used in cosmetics, in particular for manufacturing of sunscreen compositions in the form of emulsions.
  • conventional cosmetic adjuvants in particular chosen from fatty substances, organic solvents, thickeners, softeners, antioxidants, opacifiers, stabilizers, emollients, hydroxy acids, anti-aging agents. foam, moisturizing agents, vitamins, perfumes, preservatives, surfactants, fillers, sequestrants, propellants, alkalizing or acidifying agents, colorants, or any other ingredient usually used in cosmetics, in particular for manufacturing of sunscreen compositions
  • the fatty substances can consist of an oil or a wax or their mixtures, and they also include fatty acids, fatty alcohols and fatty acid esters.
  • the oils can be chosen from animal, vegetable, mineral or synthetic oils and in particular from petroleum jelly oil, paraffin oil, silicone oils, volatile or not, isoparaffins, fluorinated and perfluorinated oils.
  • the waxes can be chosen from animal, fossil, vegetable, mineral or synthetic waxes known per se.
  • organic solvents mention may be made of lower alcohols and polyols.
  • the thickeners can be chosen in particular from crosslinked acrylic acid homopolymers, guar gums and modified or unmodified celluloses such as hydroxypropylated guar gum, methylhydroxyethylcellulose, hydroxypropylmethyl cellulose or even hydroxyethylcellulose.
  • compositions of the invention can be prepared according to techniques well known to those skilled in the art, in particular those intended for the preparation of emulsions of oil-in-water or water-in-oil type, or alternatively anhydrous compositions.
  • This composition can be presented in particular in the form of a simple or complex emulsion (O / W, W / O, O / W / O or W / O / W) such as a cream, a milk, a gel or a cream gel, powder, solid composition, flexible pasta and optionally be packaged as an aerosol and be in the form of a foam or spray.
  • a simple or complex emulsion O / W, W / O, O / W / O or W / O / W
  • the aqueous phase thereof may comprise a nonionic vesicular dispersion prepared according to known methods (Bangham, Standish and Watkins. J. Mol. Biol. 13, 238 (1965), FR2315991 and FR2416008).
  • the cosmetic composition of the invention can be used as a composition for protecting the human epidermis or the hair against ultraviolet rays, as a sunscreen composition or as a make-up product.
  • the cosmetic composition according to the invention when used for the protection of the human epidermis against UV rays, or as an antisun composition, it may be in the form of a suspension or of dispersion in solvents or fatty substances, in the form of nonionic vesicular dispersion or alternatively in the form of an emulsion, preferably of the oil-in-water type, such as a cream or a milk, in the form of an ointment, gel, cream gel, stick, flexible pasta, aerosol or spray foam.
  • the cosmetic composition according to the invention when used for protecting the hair, it can be in the form of a shampoo, lotion, gel, emulsion, nonionic vesicular dispersion and constitute, for example, a composition to be rinsed, applying before or after shampooing, before or after coloring or bleaching, before, during or after perming or straightening, a styling or treating lotion or gel, a lotion or gel for brushing or setting, a composition of perm or hair straightening, coloring or bleaching.
  • composition When the composition is used as an eyelash, eyebrow or skin makeup product, such as epidermis treatment cream, foundation, lipstick stick, eyeshadow, blush, mascara or liner also called “eyeliner", it can be in solid or pasty, anhydrous or aqueous form, such as oil in water or water in oil emulsions, nonionic vesicular dispersions or even suspensions.
  • eyelash eyebrow or skin makeup product
  • anhydrous or aqueous form such as oil in water or water in oil emulsions, nonionic vesicular dispersions or even suspensions.
  • the aqueous phase (comprising in particular hydrophilic filters) generally represents from 50 to 95% by weight, preferably from 70 to 90% by weight, relative to the whole of the formulation
  • the oily phase (comprising in particular lipophilic filters) from 5 to 50% by weight, preferably from 10 to 30% by weight, relative to the whole of the formulation
  • the emulsifier (s) from 0.5 to 20% by weight, preferably from 2 at 10% by weight, relative to the entire formulation.
  • Another subject of the invention is the use of the combination of at least one agent which filters ultraviolet radiation and one or more agents stimulating the synthesis of melanin, in a composition or for the preparation of a bronzing filter composition.
  • the subject of the invention is also a method of cosmetic treatment of the skin intended to protect it against the effects of UV rays while giving it a natural tan consisting in applying to the skin an effective amount of a product as defined above. or a cosmetic composition comprising it.
  • compositions illustrate the invention without limiting it in any way.
  • proportions indicated are percentages by weight.
  • Leaves of plants of Chrysanthemum sinensis grown in a greenhouse are removed and dried for 48 hours in a ventilated oven at a temperature of 45 ° C.
  • the dried leaves are then reduced to powder by grinding on a knife grinder of the Culatti type.
  • the powder obtained is sieved on a grid whose holes have a diameter of 1 mm. It is this sifted powder that is used for the preparation of the extract.
  • the powder is mixed with an aqueous extraction solvent consisting of DMEM / F cell culture medium 12.3: 1 sold by the company Life Technologies, at a concentration of 5 grams of dry powder per 100 ml of solvent .
  • the mixture is stirred for 4 hours at room temperature.
  • the mixture is then centrifuged at 1000 rpm for 8 minutes and the supernatant is removed and subjected to two identical centrifugation / removal cycles.
  • the last supernatant removed is filtered through a 0.22 ⁇ m Millipore type filter under aseptic conditions in order to be sterilized and stored at a temperature of 4 ° C. until use.
  • the powder is mixed with sterile demineralized water having a pH of 6.5 at a concentration of 2.5 grams of dry powder per 100 ml of water.
  • the mixture is stirred for 30 minutes at room temperature.
  • the mixture is then filtered on GFD membranes sold by the company Whatmann having a porosity of 0.7 ⁇ .
  • the filtrate obtained is then filtered on a 0.22 ⁇ m Nalgene type filter under aseptic conditions in order to be sterilized and stored at a temperature of 4 ° C. until use.
  • Protocol 3 The previous protocol is carried out by replacing the water with an aqueous extraction solvent consisting of DMEM / F 12 cell culture medium, 3: 1 sold by the company Life Technologies.
  • Protocol 4 The extract obtained in Protocol 2 is lyophilized at 30 ° C after freezing at -20 ° C. The powder obtained is used directly.
  • EXAMPLE 2 Measurement of the Photoprotective and Propigmenting Effect of the Association of Mexoryl SX® (3.3 '- (1,' phenylenedimethylidyne) bis (7,7dimethyi-2-oxobicyclo [2,2,1] heptane-1 -methanesulfonicacid) with either an extract of Burnet or an extract of Chrysanthemum sinensis obtained by protocol 2 of Example 1.
  • the photoprotective and propellant effect of the association was tested on co-cultures of normal human keratinocytes / melanocytes according to the method described in patent FR95 06491 by evaluation of melanogenesis induced by UV.
  • the rate of melanin synthesis is evaluated by the incorporation of thiouracil labeled with C 14 . It is related to the amount of protein.
  • Normal human keratinocytes (NHK) and normal human melanocytes (NHM) are grown from foreskin skin. Both types of cells are amplified and stored frozen. Eight days before the test, each of the cell types is returned to culture.
  • the keratinocytes are cultured according to the method described by Rheinwald and Green (Cell (1975) 6, 331-334) on feeder cells (fibroblasts 3T3) in the growth medium Green 7F (DMEM / F12 3: 1, fetal calf serum (Gibco) 10%, adenine 0.18 mM, epidermal growth factor EGF 10 ng / ml, hydrocortisone 0.4 ⁇ g / ml; insulin 5 ⁇ g / ml, isoproterenole 10 ⁇ M, transferrin 5 ⁇ g / ml, triiodothyronine, 2nM).
  • the melanocytes are amplified in the M2 medium (Olsson, M.J. et al
  • the culture medium is replaced daily by the UV medium (DMEM / F12 3: 1 without phenol red, calf serum defined 2% (HyClone), EGF 10 ng / ml, factor ⁇ -type fibroblastic growth ( ⁇ FGF) 10 ng / ml)
  • the UV pigmentation induction is carried out by solar simulation (SSR) using a 1000 Watts Oriel Xenon solar simulator including a 280-400nm dichroic filter (Oriel, model 81035) and a WG 320 filter of Schott brand with a cut-off wavelength of 311nm (corresponding to a thickness of about 1.5mm).
  • the cell cultures are irradiated once a day for 4 days in a phosphate buffer solution (PBS).
  • PBS phosphate buffer solution
  • the propigmenting molecules are brought into contact with the cells in PBS during the irradiation and added to the culture medium (UV medium) after the irradiation.
  • Burnet extract is tested at 0.005%. It is prepared in a stock solution at 0.005%. It is prepared in a stock solution at 0.005%. It is prepared in a stock solution at 0.005%. It is prepared in a stock solution at 0.005%. It is prepared in a stock solution at 0.005%. It is prepared in a stock solution at 0.005%. It is prepared in a stock solution at 0.005%. It is prepared in a stock solution at 0.005%. It is prepared in a stock solution at
  • Tyrosine which serves as a positive control, is tested at 500 ⁇ M.
  • Mexoryl SX® is tested at 8%
  • the formulations containing the solar filter are applied at the rate of 1.4 mg / cm 2 on a quartz slide on which there is a strip of Transpore® according to a method derived from that used for determining the indices. in vitro sunscreen described by Diffey and Robspn (J Soc Cosmet Chemists (1989) 300, 230-235). The assembly is placed above the co-cultures for the duration of the irradiation.
  • the cells After irradiation, the cells are incubated in UV medium containing 1 ⁇ Ci / ml of thiouracil labeled with C 14 .
  • the cells are rinsed in phosphate buffer.
  • the proteins are precipitated using 5% trichloroacetic acid (TCA) and washed in order to remove the free radioactivity.
  • TCA 5% trichloroacetic acid
  • the cells are lysed overnight at 40 ° C. using a proteinase K solution at 100 ⁇ g / ml in Tris HCl-triton-EDTA buffer. 5 ⁇ l of total extract are taken and transferred to a 96-well plate (Wallac) for the protein assay which is carried out with the MicroBCA * Protein Assay Reagent kit (Pierce).
  • the rest of the extract i.e. 950 ⁇ l, is filtered on a DEAE Filtermat filter. After rinsing, the filter covered with the solid glitter "Meltilex" is transferred to a plate. Radioactivity is counted using the Wallac counter. The results are expressed as a percentage of the control control, or of the solvent control if the product is dissolved in a solvent other than water, according to the formulas:
  • 4 CP is the average of the disintegrations per minute (dpm) thiouracil 14 C on 3 similar wells treated with a product (P);
  • Qty protein P is the average amount of protein in the corresponding wells (in milligrams).
  • 14 CT is the average of 14 C thiouracil dpm over 3 similar control wells (T); .
  • Qty protein T is the average amount of protein in the corresponding wells (in milligrams),
  • 14 CS is the average of the thiouracil dpm 14 C over 3 similar wells solvent controls (S); protein S quantity is the average of the quantities of protein in the corresponding wells (in milligrams). Results:% variation in melanin synthesis compared to control (cells not treated with the product and not irradiated)
  • a dry extract of the root and rhizome of Sanguisorba officinalis is added to this composition, which can in particular be obtained in powder form from MARUZEN PHARMACEUTICALS CO., LTD (Burnet Extract Powder), so that its concentration in the finished product is from 1 %.
  • Example 4 Bronzing and filtering composition to be applied to the skin containing chrysanthemum sinensis at 1%
  • a chryticianhemum sinensis extract obtained according to FR 2768343 is added to this composition, so that its concentration in the finished product is 1%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Cosmetics (AREA)

Abstract

The invention concerns a product comprising at least a UV radiation filtering agent and at least a compound stimulating melanin synthesis, a composition comprising at least said product and the use of said product in a composition or for preparing a composition designed to protect the skin against the harmful action of UV radiation, as well as a cosmetic skin treatment method.

Description

Produit bronzant et filtrant Tanning and filtering product
L'invention a pour objet un produit comprenant au moins un agent filtrant les rayonnements ultraviolets et au moins un composé stimulant la synthèse de la. mélanine, une composition comprenant au moins ledit produit, l'utilisation dudit produit dans une composition ou pour la préparation d'une composition destinée à protéger la peau de l'action néfaste des rayonnements ultraviolets, ainsi qu'un procédé de traitement cosmétique de la peau.The subject of the invention is a product comprising at least one agent which filters ultraviolet radiation and at least one compound which stimulates the synthesis of. melanin, a composition comprising at least said product, the use of said product in a composition or for the preparation of a composition intended to protect the skin from the harmful action of ultraviolet radiation, as well as a method of cosmetic treatment of the skin.
Le rayonnement solaire est composé, entre autres, de rayonnement ultraviolet de type A de longueurs d'onde comprises entre 320 nm et 400 nm (UV-A), de rayonnements ultraviolets de type B de longueurs d'onde comprises entre 280 et 320 nm (UV-B) et de rayonnements ultraviolets de type C de longueurs d'onde comprises entre 200 et 280 nm (UV-C).Solar radiation is composed, among other things, of type A ultraviolet radiation of wavelengths between 320 nm and 400 nm (UV-A), of type B ultraviolet radiation of wavelengths between 280 and 320 nm (UV-B) and type C ultraviolet radiation of wavelengths between 200 and 280 nm (UV-C).
Les UV-B sont fortement énergétiques et peu pénétrants, faiblement représentés dans la lumière solaire, dépendants des variations climatiques (temps nuageux, couvert, etc.) et leur présence varie en fonction des heures de la journée (notion de pic (zénith)). Les UV-A sont moins énergétiques que les UV-B mais plus pénétrants, présents en grande quantité dans la lumière solaire (au minimum 100 fois plus d'UV-A que d'UV-B), peu dépendants des variations climatiques et présents quelle que soit l'heure de la journée. Les UV-C sont fortement énergétiques et peu pénétrants. Ils sont stoppés par la couche d'ozone et théoriquement n'arrivent pas sur la terre. Mais potentiellement ils peuvent être responsables de dégâts des acides nucléiques.UV-B are highly energetic and not very penetrating, poorly represented in sunlight, dependent on climatic variations (cloudy weather, overcast, etc.) and their presence varies according to the hours of the day (notion of peak (zenith)) . UV-A is less energetic than UV-B but more penetrating, present in large quantities in sunlight (at least 100 times more UV-A than UV-B), little dependent on climatic variations and present whatever time of day. UV-C is highly energetic and not very penetrating. They are stopped by the ozone layer and theoretically do not arrive on earth. But potentially they can be responsible for damage to nucleic acids.
Il est connu que le rayonnement solaire est responsable d'effets bénéfiques sur la peau, comme par exemple le brunissement, mais qu'il est aussi susceptible d'induire des dommages de celle-ci, notamment dans le cas d'une peau dite "sensible" ou d'une peau continuellement exposée. Au titre des bienfaits le brunissement, communément appelé bronzage, est un élément essentiel du système de défense de la peau. En effet en réponse aux rayonnements ultraviolets, les mélanocytes de la couche basale de l'épidémie synthétisent de la mélanine qui une fois incorporée aux kératinocytes constitue un filtre naturel situé à la surface de la peau, filtre qui absorbe le rayonnement ultraviolet. La mélanine, sous forme de particule, peut agir également comme écran réfléchissant les UV. Ceci a pour objectif de diminuer la quantité de rayonnement ultraviolet qui traverse les couches de la peau afin de l'empêcher d'atteindre les couches profondes et d'y causer des dommages néfastes pour la peau.It is known that solar radiation is responsible for beneficial effects on the skin, such as browning, but that it is also capable of inducing damage thereof, in particular in the case of so-called skin " sensitive "or continuously exposed skin. As a benefit, browning, commonly known as tanning, is an essential part of the skin's defense system. In fact, in response to ultraviolet radiation, the melanocytes in the basal layer of the epidemic synthesize melanin which, once incorporated into keratinocytes, constitutes a natural filter located on the surface of the skin, a filter which absorbs ultraviolet radiation. Melanin, in the form of a particle, can also act as a UV-reflecting screen. This is intended to decrease the amount of ultraviolet radiation that passes through the layers of the skin in order to prevent it from reaching the deep layers and causing harmful damage to the skin.
On sait par ailleurs combien il est important d'avoir une bonne mine et combien une peau bronzée est toujours signe de bonne santé. D'où l'engouement pour des expositions prolongées aux rayonnements ultraviolets pour acquérir un bronzage suffisant.We also know how important it is to look good and how tanned skin is always a sign of good health. Hence the craze for prolonged exposure to ultraviolet radiation to acquire a sufficient tan.
Cependant, au titre des effets nocifs, on sait qu'une exposition excessive de la peau aux rayonnements solaires, et aux rayonnements ultraviolets en particulier, peut entraîner un changement dans l'élasticité de la peau, dans sa teneur en certains composés, et ainsi favoriser l'accélération du processus naturel de vieillissement de la peau. Ce processus de vieillissement accéléré ou prématuré dû aux rayonnements! ultraviolets est généralement appelé photo-vieillissement ou vieillissement actinique ou dermatohéliose. Les UV-B faiblement pénétrants atteignent principalement l'épiderme. Le rôle des UV-B a été clairement démontré dans l'induction de cancers de la peau UV-induits. Ils ont en effet comme principal chromophore les acides nucléiques en particulier l'acide désoxyribonucléique, au sein duquel ils induisent des lésions et/ou des mutations (Eller M.S., 1995, in Photodamage. 26-56, Blackwell éd.). Les UV A qui traversent l'épiderme etatteignent le derme, sont fortement impliqués dans le photovieillissement de la peau : ils contribuent par exemple à l'apparition de l'élastose solaire. Par ailleurs, il est connu que les réactions de photosensibilisation et les photodermatoses telles que la dermite polymorphe sont médiées principalement par les UVA..However, as harmful effects, it is known that excessive exposure of the skin to solar radiation, and to ultraviolet radiation in particular, can cause a change in the elasticity of the skin, in its content of certain compounds, and so promote the acceleration of the skin's natural aging process. This accelerated or premature aging process due to radiation! Ultraviolet is generally called photoaging or actinic aging or dermatoheliosis. Weakly penetrating UV-B mainly affects the epidermis. The role of UV-B has been clearly demonstrated in the induction of UV-induced skin cancer. In fact, their main chromophore is nucleic acids, in particular deoxyribonucleic acid, within which they induce lesions and / or mutations (Eller MS, 1995, in Photodamage. 26-56, Blackwell ed.). The UV A rays which cross the epidermis and reach the dermis, are strongly involved in photoaging of the skin: they contribute for example to the appearance of solar elastosis. Furthermore, it is known that photosensitization reactions and photodermatoses such as polymorphic dermatitis are mediated mainly by UVA.
Les UVA sont également mutagéniques (Stary A. Mutation Res. 1997 ; 398 : 1-8) et photocarcinogènes ( De Laat A., 1998, in Protection of the skin against ultraviolet radiations. 19-23, John Libbey Eurotext ed) et en addition avec les UVB, peuvent contribuer au développement des cancers cutanés.UVA is also mutagenic (Stary A. Mutation Res. 1997; 398: 1-8) and photocarcinogenic (De Laat A., 1998, in Protection of the skin against ultraviolet radiations. 19-23, John Libbey Eurotext ed) and in addition with UVB, can contribute to the development of skin cancer.
Avec le développement des salons de bronzage ou l'utilisation de lampe UVA à domicile favorisant une exposition massive et prolongée aux UVA, il est montré que les UVA altèrent le mélanocyte et provoquent l'apparition de tâches pigmentaires (lentîgo) et l'augmentation du risque de développer un mélanome (RϋngerTM Photodermatol. Photoimmunol. Photmed. 1999 ; 15-212-216)With the development of tanning salons or the use of UVA lamps at home favoring massive and prolonged exposure to UVA, it is shown that UVA alter the melanocyte and cause the appearance of pigmentation spots (lentîgo) and the increase in risk of developing melanoma (RϋngerTM Photodermatol. Photoimmunol. Photmed. 1999; 15-212-216)
On comprend donc le dilemme qui existe à d'un côté vouloir s'exposer au rayonnement ultraviolet pour présenter un aspect bronzé et d'un autre côté l'absolue nécessité de se protéger de ces mêmes rayonnements du fait de leurs effets nocifs.We therefore understand the dilemma which exists on the one hand wanting to expose oneself to ultraviolet radiation to present a tanned appearance and on the other hand the absolute need to protect oneself from these same radiations because of their harmful effects.
Jusqu'à présent une des solutions proposées est de fournir des compositions comprenant un agent filtrant possédant un indice de protection moyen permettant à la fois une certaine protection et un certain brunissement. En effet, si l'agent filtrant est en quantité élevée, il va d'autant plus limiter la stimulation par les ultraviolets de la synthèse de la mélanine par les mélanocytes. A l'inverse, une composition contenant une quantité faible ou moyenne d'agent filtrant ne présente pas les garanties suffisantes en terme de protection contre les effets néfastes du rayonnement ultraviolet, ni ne procure une satisfaction suffisante en terme d'obtention d'un brunissement. Par ailleurs, il a été proposé certaines associations pour renforcer le brunissement de la peau, avec un filtre solaire.Until now, one of the solutions proposed is to provide compositions comprising a filtering agent having an average protection index allowing both a certain protection and a certain browning. Indeed, if the filtering agent is in high quantity, it will all the more limit the stimulation by the ultraviolet rays of the synthesis of melanin by the melanocytes. Conversely, a composition containing a small or medium amount of filtering agent does not have sufficient guarantees in terms of protection against the harmful effects of ultraviolet radiation, nor does it provide sufficient satisfaction in terms of obtaining browning. . In addition, certain associations have been proposed to reinforce the browning of the skin, with a sunscreen.
Des compositions contenant des dérivés de psoralène et un agent filtrant ont ainsi été décrites dans FR 2409751 ou FR 2797585. Toutefois, pour favoriser la pigmentation, les dérivés de psoralène tel le 5-méthoxy psoralène nécessitent une irradiation simultanée de la peau par des doses d'UVA , qui peuvent endommager l'ADN; en outre, l'emploi de tels dérivés de psoralène n'est pas souhaitable car ils pourraient être impliqués dans des réactions de photosensibilisation. Des associations de filtres UV avec de la tyrosine ou des xanthines ont également été proposées, notamment dans FR 2 624374 ou FR 2607699; toutefois, l'activité de ces préparations n'est pas démontrée, et elles nécessitent également une irradiation notable de la peau, et souvent des adjuvants supplémentaires. CH 642357 décrit des compositions contenant des dérivés de la tyrosine des filtres UV et des dérivés chromophores.Compositions containing psoralen derivatives and a filtering agent have thus been described in FR 2409751 or FR 2797585. However, to promote pigmentation, psoralen derivatives such as 5-methoxy psoralen require simultaneous irradiation of the skin with doses of 'UVA, which can damage DNA; in addition, the use of such psoralen derivatives is not desirable since they could be involved in photosensitization reactions. Combinations of UV filters with tyrosine or xanthines have also been proposed, in particular in FR 2 624 374 or FR 2 607 699; however, the activity of these preparations has not been demonstrated, and they also require significant irradiation of the skin, and often additional adjuvants. CH 642357 describes compositions containing tyrosine derivatives of UV filters and chromophoric derivatives.
WO 91/07945 ou EP 380335 proposent l'utilisation de xanthines pour favoriser le bronzage, éventuellement associées à un filtre solaire. Toutefois, l'efficacité des xanthines en tant qu'agent de brunissement chez l'homme n'est pas satisfaisante. WO 98/25584 revendique des compositions anti-inflammatoires et activant la mélanogénèse contenant des dérivés d'α MSH et de la SOD, auxquels on peut adjoindre de l'oxyde de titane. Il est connu que les dérivés de cette hormone peuvent avoir des activités sur différentes fonctions de l'organisme et en outre ont un pouvoir pro pigmentant faible.WO 91/07945 or EP 380335 propose the use of xanthines to promote tanning, possibly associated with a sunscreen. However, the efficacy of xanthines as a browning agent in humans is not satisfactory. WO 98/25584 claims anti-inflammatory and activating melanogenesis compositions containing α MSH and SOD derivatives, to which titanium oxide can be added. It is known that derivatives of this hormone can have activities on various functions of the organism and in addition have a weak pro-pigmenting power.
Il persiste donc un besoin en composition filtrante qui d'une part présenteraient un pouvoir filtrant élevé et d'autre part une capacité à stimuler le brunissement dans des proportions également élevées.There therefore remains a need for a filtering composition which on the one hand would have a high filtering power and on the other hand an ability to stimulate browning in equally high proportions.
La demanderesse vient maintenant de montrer que l'association d'un agent filtrant le rayonnement ultraviolet et d'un composé stimulant la synthèse de la mélanine présente un effet surprenant qui conduit à l'obtention d'un produit filtrant et bronzant ayant des qualités filtrantes et un pouvoir de stimulation de la synthèse de la méianine élevés.The Applicant has now shown that the combination of an agent filtering ultraviolet radiation and a compound stimulating the synthesis of melanin has a surprising effect which leads to the production of a filtering and tanning product having filtering qualities. and a high stimulation capacity for the synthesis of meianin.
L'invention a donc pour objet premier un produit composé par au moins l'association d'au moins un agent filtrant les rayonnements ultraviolets et d'un agent stimulant la synthèse de la mélanine.The primary object of the invention is therefore a product composed by at least the combination of at least one agent which filters ultraviolet radiation and one agent which stimulates the synthesis of melanin.
Ces compositions résolvent le problème d'obtenir un brunissement et protection de la peau équivalente à celle obtenue après une exposition solaire sans la soumettre aux risques induits par une irradiation par les rayonnements UV, en particulier les UVA. L'invention a aussi pour objet une composition comprenant au moins l'association d'au moins un agent filtrant les rayonnements ultraviolets et d'un agent stimulant la synthèse de la mélanine.These compositions solve the problem of obtaining browning and protection of the skin equivalent to that obtained after sun exposure without subjecting it to the risks induced by irradiation by UV radiation, in particular UVA rays. The subject of the invention is also a composition comprising at least the combination of at least one agent which filters ultraviolet radiation and one agent which stimulates the synthesis of melanin.
De préférence, l'agent stimulant la synthèse de mélanine est un agent qui n'est pas susceptible d'entraîner d'effets secondaires systémiques sur l'organisme, notamment hormonaux, ni des phénomènes de photosensibilisation.Preferably, the agent stimulating the synthesis of melanin is an agent which is not likely to cause systemic side effects on the organism, in particular hormonal, nor phenomena of photosensitization.
L'agent filtrant les rayonnements ultraviolets est de préférence choisi parmi les filtres organiques et/ou les filtres minéraux.The ultraviolet radiation filtering agent is preferably chosen from organic filters and / or mineral filters.
Comme filtres organiques on peut notamment citer les dérivés cinnamiques, les dérivés salicyliques, les dérivés du camphre, les dérivés de triazine, les dérivés de la benzophénone, les dérivés du dibenzoylméthane, les dérivés de β,β- diphénylacrylate, les dérivés de l'acide p-aminobenzoïque, les polymères filtres et silicones filtres décrits dans la demande WO-93/04665ou encore les filtres organiques décrits dans la demande de brevet EP-A 0487404.As organic filters, mention may be made in particular of cinnamic derivatives, salicylic derivatives, camphor derivatives, triazine derivatives, benzophenone derivatives, dibenzoylmethane derivatives, β, β-diphenylacrylate derivatives, derivatives of p-aminobenzoic acid, the filter polymers and filter silicones described in application WO-93/04665 or also the organic filters described in patent application EP-A 0487404.
Comme filtres minéraux on peut notamment citer des pigments ou bien encore des nanopigments (taille moyenne des particules primaires : généralement entre 5 nm et 100 nm, de préférence entre 10 et 50 nm) d'oxydes métalliques enrobés ou non comme par exemple des nanopigments d'oxyde de titane (amorphe ou cristallisé sous forme rutile et/ou anatase), de fer, de zinc, de zirconium ou de cérium qui sont tous des agents photoprotecteurs bien connus en soi agissant par blocage physique (réflection et/ou diffusion) du rayonnement UV. Des agents d'enrobage classiques sont par ailleurs l'alumine et/ou le stéarate d'aluminium. De tels nanopigments d'oxydes métalliques, enrobés ou non enrobés, sont en particulier décrits dans les demandes de brevets EP-A- 0 518 772 et EP-A- 0 518As mineral filters, mention may in particular be made of pigments or else nanopigments (average size of the primary particles: generally between 5 nm and 100 nm, preferably between 10 and 50 nm) of metallic oxides coated or not, such as for example nanopigments of titanium oxide (amorphous or crystallized in rutile form and / or anatase), iron, zinc, zirconium or cerium which are all well known photoprotective agents acting by physical blocking (reflection and / or diffusion) of UV radiation. Conventional coating agents are moreover alumina and / or aluminum stearate. Such nanopigments of metallic oxides, coated or uncoated, are in particular described in patent applications EP-A- 0 518 772 and EP-A- 0 518
773. Comme exemples de filtres solaires actifs dans l'UV-A et/ou l'UV-B, on peut citer :773. Examples of active solar filters in UV-A and / or UV-B include:
l'acide p-aminobenzoïque, le p-aminobenzoate oxyéthyléné (25mol), le p-diméthylaminobenzoate de 2-éthylhexyle, le p-aminobenzoate d'éthyle N-oxypropyléné le p-aminobenzoate de glycérol, le salicylate d'homomenthyle, le salicylate de 2-éthylhexyle, le salicylate de triéthanolamine, le salicylate de 4-isopropylbenzyle, le 4-ter-butyl-4'-méthoxy-dibenzoylméthane, le 4-isopropyl-dibenzoylméthane, l'anthranilate de menthyle, le 2-éthylhexyl-2-cyano-3,3'-diphénylacrylate, l'éthyl-2-cyano-3,3'-diphénylacrylate, l'acide 2-phényl benzimidazole 5-sulfonique et ses sels, le 3-(4'-triméthylammonium)-benzylidèn-boman-2-on-méthylsulfate, le 2-hydroxy-4-méthoxybenzophénone, le 2-hydroxy-4-méthoxybenzophénone-5-sulfonate, le 2,4-dihydroxybenzophénone, le 2,2',4,4'-tétrahydroxybenzophénone, le 2,2'-dîhydroxy-4,4'diméthoxybenzophénone, le 2-hydroxy-4-n-octoxybenzophénone, le 2-hydroxy-4-méthoxy-4'-méthylbenzophénone, l'acide α-(2-oxoborn-3-ylidène)-tolyl-4-sulfonique et ses sels le 3-(4'-sulfo)benzylidèn-bornan-2-one et ses sels, le 3-(4'méthylbenzylidène)-d,l-camphre, le 3-benzylidène-d,l-camphre, l'acide benzène 1,4-di(3-méthylidène-10-camphosulfonique) et ses sels, l'acide urocanique, la 2,4,6-tris-[ p-(2'-éthylhexyl-1'-oxycarbonyl)anilino]-1 ,3,5-triazine, 2-[(p-(tertiobutylamido)anilino]-4,6-bis-[(p-(2'-éthylhexyl-1'-oxycarbonyl)anilino]-p-aminobenzoic acid, oxyethylenated p-aminobenzoate (25mol), 2-ethylhexyl p-dimethylaminobenzoate, N-oxypropylenated ethyl p-aminobenzoate, glycerol p-aminobenzoate, homomenthyl salicylate, 2-ethylhexyl salicylate, salicylate of triethanolamine, 4-isopropylbenzyl salicylate, 4-ter-butyl-4'-methoxy-dibenzoylmethane, 4-isopropyl-dibenzoylmethane, menthyl anthranilate, 2-ethylhexyl-2-cyano-3,3 ' -diphenylacrylate, ethyl-2-cyano-3,3'-diphenylacrylate, 2-phenyl benzimidazole 5-sulfonic acid and its salts, 3- (4'-trimethylammonium) -benzyliden-boman-2-on- methylsulfate, 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxybenzophenone-5-sulfonate, 2,4-dihydroxybenzophenone, 2,2 ', 4,4'-tetrahydroxybenzophenone, 2,2'- 4,4-hydroxy-dimethoxybenzophenone, 2-hydroxy-4-n-octoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, α- (2-oxoborn-3-ylidene) -tolyl- acid 4-sulfonic and its salts on 3- (4'-sul fo) benzyliden-bornan-2-one and its salts, 3- (4'methylbenzylidene) -d, l-camphor, 3-benzylidene-d, l-camphor, benzene acid 1,4-di (3 -methylidene-10-camphosulfonic) and its salts, urocanic acid, 2,4,6-tris- [p- (2'-ethylhexyl-1'-oxycarbonyl) anilino] -1, 3,5-triazine, 2 - [(p- (tert-butylamido) anilino] -4,6-bis - [(p- (2'-ethylhexyl-1'-oxycarbonyl) anilino] -
1,3,5-triazine, la 2,4-bis {[4-2-éthyl-hexyloxy)]-2-hydroxy]-phenyl}-6-(4-méthoxy-phenyl)-1 ,3,5- triazine ; le polymère de N-(2 et 4)-[(2-oxobom-3-ylidèn)méthyl] benzylj-acrylamide, l'acide 4,4-bis-benzimidazolyl-phénylèn-3,3',5,5'-tétrasulfonique et ses sels le 2,2'-méthylèn-bis-[6-(2H-benzotriazol-2-yl)-4-(1 ,1 ,3,3-tétraméthylbutyl)phénol]. les polyorganosiloxanes à fonction malonate.1,3,5-triazine, 2,4-bis {[4-2-ethyl-hexyloxy)] - 2-hydroxy] -phenyl} -6- (4-methoxy-phenyl) -1, 3,5- triazine; the polymer of N- (2 and 4) - [(2-oxobom-3-yliden) methyl] benzylj-acrylamide, 4,4-bis-benzimidazolyl-phenylen-3,3 ', 5,5'- acid tetrasulfonic acid and its 2,2'-methylen-bis- [6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) phenol] salts. polyorganosiloxanes with a malonate function.
La quantité de composé reconnu comme agent filtrant des rayonnements ultraviolets, contenue dans la composition de l'invention est bien entendu fonction de l'effet recherché et peut donc varier dans une large mesure.The amount of compound recognized as a filtering agent for ultraviolet radiation, contained in the composition of the invention is of course a function of the desired effect and can therefore vary to a large extent.
De préférence on utilisera des agents capables de filtrer substantiellement les rayonnements UV A. Selon un mode de réalisation avantageux de l'invention, l'I P UVA (indice de protection UVA) déterminé selon la méthode de la JCIA (Japonese Cosmetic Industry Association, Measurement standards for UVA efficacy. Tokyo, Japan : 1995) sera de 5 à 20, de préférence de 8 à 15.Preferably, agents capable of substantially filtering UV A radiation will be used. According to an advantageous embodiment of the invention, the I P UVA (UVA protection index) determined according to the method of the JCIA (Japonese Cosmetic Industry Association, Measurement standards for UVA efficacy. Tokyo, Japan: 1995) will be 5 to 20, preferably 8 to 15.
Avantageusement, la préparation filtrante présentera un pouvoir de protection solaire ou SPF (sun protection factor) déterminé selon la méthode Colipa ( The european cosmetic toiletry and perfumery association (Colipa). Sun protection factor method. Report 94/289. Brussels Belgium,1994) au moins égal à 10 et inférieur ou égal à 60, de préférence de 15 à 30.Advantageously, the filter preparation will have a sun protection factor or SPF (sun protection factor) determined according to the Colipa method (The european cosmetic toiletry and perfumery association (Colipa). Sun protection factor method. Report 94/289. Brussels Belgium, 1994) at least equal to 10 and less than or equal to 60, preferably from 15 to 30.
La préparation filtrante contiendra ainsi une quantité en filtres UVB et UVA de telle manière à associer à un SPF élevé , un IP UVA également élevé.The filter preparation will thus contain a quantity of UVB and UVA filters so as to combine with a high SPF, an IP UVA also high.
Des filtres particulièrement adaptés à la mise en œuvre de l'invention seront choisis dans le groupe comprenant le salicylate de 2-éthylhexyle, le 4-ter-butyl-4'- méthoxy-dibenzoylméthane, le 2-hydroxy-4-méthoxybenzophénone-5-sulfonate, l'acide benzène 1,4~di(3-méthylidène-10-camphosulforιique) et ses sels, et les mélanges de ces composés.Filters particularly suitable for the implementation of the invention will be chosen from the group comprising 2-ethylhexyl salicylate, 4-ter-butyl-4'-methoxy-dibenzoylmethane, 2-hydroxy-4-methoxybenzophenone-5 -sulfonate, benzene acid 1,4 ~ di (3-methylidene-10-camphosulforιique) and its salts, and mixtures of these compounds.
Pour donner un ordre de grandeur, la quantité d'agents filtrants des rayonnements ultraviolets contenue dans la composition est en une quantité représentant de 0,1% à 25% du poids total de la composition, notamment de 6 à 25%; avantageusement elle sera d'au moins 8%, et de manière préférée inférieure ou égale à 15% du poids total de la composition; selon un autre mode de réalisation avantageux de l'invention les agents filtrants sont présents en une quantité représentant de 0,5% à 10% du poids total de la composition.To give an order of magnitude, the quantity of filtering agents for ultraviolet radiation contained in the composition is in an amount representing from 0.1% to 25% of the total weight of the composition, in particular from 6 to 25%; advantageously it will be at least 8%, and preferably less than or equal to 15% of the total weight of the composition; according to another advantageous embodiment of the invention, the filtering agents are present in an amount representing from 0.5% to 10% of the total weight of the composition.
Le ou les agents stimulant la synthèse de la mélanine peuvent être choisi parmi :The agent (s) stimulating the synthesis of melanin can be chosen from:
-des analogues de substrats de la tyrosinase, enzyme clé de la mélanogénèse tels que la tyrosine, la L-dopa ou la L-dihydroxylphenylalanine- analogs of substrates of tyrosinase, a key enzyme in melanogenesis such as tyrosine, L-dopa or L-dihydroxylphenylalanine
- des activateurs de l'activité ou de l'expression de la tyrosinase tels que la forskoline, les bases xanthiques ( théophylline, caféine), les peptides pro- opiomélanocortiques (ACTH, alpha-MSH ou autres agonistes de des récepteurs MC1), les diacylglycérols, les diols aliphatiques ou cycliques, les psoralènes, les prostaglandines et analogues, les activateurs de la protéine kinase G NO/cGMP dépendante, - - des activateurs de transfert des mélanosomes vers les kératinocytes tels que les serine protéases ou d'agonistes des récepteurs PAR-2.activators of the activity or expression of tyrosinase such as forskolin, xanthic bases (theophylline, caffeine), pro-opiomelanocortic peptides (ACTH, alpha-MSH or other agonists of MC1 receptors), diacylglycerols, aliphatic or cyclic diols, psoralens, prostaglandins and the like, activators of protein kinase G NO / cGMP dependent, - activators of transfer of melanosomes to keratinocytes such as serine proteases or receptor agonists BY 2.
Préférentiellement selon l'invention on utilise un extrait obtenu à partir d'un végétal, notamment de Burnet (Sanguisorba officinalis) ou encore un extrait d'au moins un végétal du genre Chrysanthemum, particulièrement de l'espèce Chrysanthemum sinensis.Preferably, according to the invention, an extract obtained from a plant, in particular from Burnet (Sanguisorba officinalis), is used, or an extract from at least one plant of the genus Chrysanthemum, particularly of the species Chrysanthemum sinensis.
En effet, de manière surprenante, la demanderesse a mis en évidence que de tels extraits induisent unestimulation remarquable de la mélanogénèse et donc de brunissement, et ce même en l'absence d'irradiation notable par des UV A. cet effet inattendu est très supérieur à celui obtenu avec d'autres propigmentants.In fact, surprisingly, the Applicant has demonstrated that such extracts induce a remarkable stimulation of melanogenesis and therefore of browning, even in the absence of notable irradiation by UV A rays. This unexpected effect is much greater. to that obtained with other propigmentants.
L'extrait d'au moins un végétal du genre Chrysanthemum peut être tout extrait préparé à partir de tout matériel végétal issu d'un végétal du genreThe extract of at least one plant of the genus Chrysanthemum can be any extract prepared from any plant material derived from a plant of the genus
Chrysanthemum.Chrysanthemum.
La composition peut contenir au moins un extrait d'au moins un végétal du genre Chrysanthemum obtenu à partir de matériel issu d'un végétal cultivé in vivo ou issu de culture in vitro. Par culture in vivo on entend toute culture de type classique c'est à dire en sol à l'air libre ou en serre, ou encore hors sol.The composition may contain at least one extract of at least one plant of the genus Chrysanthemum obtained from material obtained from a plant cultivated in vivo or derived from culture in vitro. The term “in vivo culture” means any culture of the conventional type, that is to say in soil in the open air or in a greenhouse, or even above ground.
On peut ainsi utiliser par exemple selon l'invention un extrait de différentes parties du végétal, feuilles, fleurs, tiges, racines, cellules indifférenciées, seules ou en mélange, que le végétal soit cultivé in vivo ou in vitro.It is thus possible, for example, according to the invention to use an extract of different parts of the plant, leaves, flowers, stems, roots, undifferentiated cells, alone or as a mixture, whether the plant is cultivated in vivo or in vitro.
La pression de sélection imposée par les conditions physico-chimiques lors de la croissance des cellules végétales in vitro permet d'obtenir un matériel végétal standardisé et disponible tout au long de l'année contrairement aux plantes cultivées in vivo.The selection pressure imposed by the physico-chemical conditions during the growth of plant cells in vitro makes it possible to obtain standardized plant material which is available throughout the year unlike plants cultivated in vivo.
Par culture in vitro, on entend l'ensemble des techniques connues de l'homme du métier qui permet de manière artificielle l'obtention d'un végétal ou d'une partie d'un végétal.The term “in vitro culture” means all of the techniques known to those skilled in the art which artificially make it possible to obtain a plant or part of a plant.
De préférence on utilise un extrait obtenu à partir de matériel végétal cultivé in vivo et encore plus préférentiellement un extrait obtenu à partir de feuilles de végétaux du genre Chrysanthemum cultivées in vivo.Preferably, an extract obtained from plant material cultivated in vivo is used, and even more preferably an extract obtained from leaves of plants of the genus Chrysanthemum cultivated in vivo.
Par extrait d'au moins un végétal du genre Chrysanthemum, on entend aussi bien un mélange brut de parties du végétal grossièrement réduites en morceaux et du solvant d'extraction que des préparations élaborées à partir des principes actifs solubilisés lors de l'extraction. On pourra notamment utiliser des extraits préparés selon les techniques décrites dans la demande FR2 768343, qui est incorporée ici par référence. Un extrait particulièrement utilisable selon l'invention est réalisé par le broyage fin de parties du végétal suivi d'une macération dans le solvant d'extraction, ledit solvant étant de préférence un solvant hydrophile, et finalement d'une filtration. Bien évidemment l'extrait selon l'invention peut être chacun des extraits ainsi obtenus utilisé seul ou en mélange avec l'un ou plusieurs des autres extraits. Toute méthode d'extraction connue de l'homme du métier peut être utilisée selon l'invention.The expression “extract of at least one plant of the genus Chrysanthemum” is understood to mean both a crude mixture of parts of the plant roughly reduced to pieces and of the extraction solvent, as well as preparations prepared from the active principles dissolved during the extraction. It will be possible in particular to use extracts prepared according to the techniques described in application FR2 768343, which is incorporated here by reference. A particularly usable extract according to the invention is produced by fine grinding of parts of the plant followed by maceration in the extraction solvent, said solvent preferably being a hydrophilic solvent, and finally by filtration. Obviously the extract according to the invention can be each of the extracts thus obtained used alone or in admixture with one or more of the other extracts. Any extraction method known to a person skilled in the art can be used according to the invention.
On peut en particulier citer les extraits aqueux, alcooliques, notamment éthanoliques, les extraits hydroalcooliques. Quelque soit la forme de l'extrait que l'on désire utiliser, les techniques utilisées pour l'obtenir sont celles généralement décrites dans l'art antérieur et bien connues de l'homme du métier.Mention may in particular be made of aqueous, alcoholic, in particular ethanolic, extracts, hydroalcoholic extracts. Whatever the form of the extract that it is desired to use, the techniques used to obtain it are those generally described in the prior art and well known to those skilled in the art.
On peut également utiliser un extrait préparé par la méthode décrite dans la demande de brevet français n° 95-02379.One can also use an extract prepared by the method described in French patent application No. 95-02379.
Ainsi, dans une première étape on broie le matériel végétal dans une solution aqueuse à froid, dans une deuxième étape les particules en suspension sont éliminées de la solution aqueuse issue de la première étape, et dans une troisième étape on stérilise la solution aqueuse issue de la deuxième étape. Cette solution aqueuse correspond à l'extrait.Thus, in a first step the plant material is ground in a cold aqueous solution, in a second step the particles in suspension are removed from the aqueous solution obtained from the first step, and in a third step the aqueous solution obtained from the second step. This aqueous solution corresponds to the extract.
D'autre part, la première étape peut avantageusement être remplacée par une opération de congélation simple des tissus végétaux (par exemple à -20°C), suivie d'une extraction aqueuse reprenant les deuxièmes et troisième étapes ci-dessus décrites. L'extrait utilisable selon l'invention pourra subir des étapes de fractionnement successives, en vue de concentrer les principes actifs. Avantageusement ,ce fractionnement sera effectué par une extraction liquide/liquide, on utilisera préférentiellement les fractions extraites par un mélange hydroalcoolique, en éliminant les fractions de tête.On the other hand, the first step can advantageously be replaced by a simple freezing operation of the plant tissues (for example at -20 ° C.), followed by an aqueous extraction repeating the second and third steps described above. The extract which can be used according to the invention may undergo successive fractionation stages, with a view to concentrating the active principles. Advantageously, this fractionation will be carried out by a liquid / liquid extraction, the fractions extracted by a hydroalcoholic mixture will preferably be used, eliminating the top fractions.
Quel que soit le mode de préparation utilisé selon l'invention des étapes subséquentes visant à favoriser la conservation et/ou la stabilisation peuvent être ajoutées sans pour cela modifier la nature même de l'extrait. Ainsi, par exemple l'extrait obtenu peut être lyophilisé par toutes méthodes classiques de lyophilisation. On obtient ainsi une poudre qui peut être utilisée directement ou bien mélanger dans un solvant approprié avant utilisation. Préférentiellement selon l'invention on utilise un extrait aqueux. Comme extrait de Burnet, on utilise préférentiellement, selon l'invention, un extrait sec de racine et de rhizome de Sanguisorba officinalis qui peut notamment être obtenu sous forme de poudre auprès de MARUZEN PHARMACEUTICALS CO., LTD (Burnet Extract Powder).Whatever the mode of preparation used according to the invention, subsequent steps aimed at promoting conservation and / or stabilization can be added without modifying the very nature of the extract. Thus, for example, the extract obtained can be lyophilized by any conventional lyophilization method. A powder is thus obtained which can be used directly or else mix in an appropriate solvent before use. Preferably according to the invention, an aqueous extract is used. As Burnet extract, use is preferably made, according to the invention, of a dry extract of the root and rhizome of Sanguisorba officinalis which can in particular be obtained in powder form from MARUZEN PHARMACEUTICALS CO., LTD (Burnet Extract Powder).
La quantité de composé stimulant la synthèse de la mélanine contenue dans la composition de l'invention est bien entendu fonction de l'effet recherché et peut donc varier dans une large mesure.The amount of compound stimulating the synthesis of melanin contained in the composition of the invention is of course a function of the desired effect and can therefore vary to a large extent.
Pour donner un ordre de grandeur, le composé stimulant la synthèse de la mélanine contenue dans la composition est en une quantité représentant de 0,01% à 15% du poids total de la composition et préférentiellement en une quantité représentant de 0.5% à 5%, notamment de 1 à 5% du poids total de la composition.To give an order of magnitude, the compound stimulating the synthesis of melanin contained in the composition is in an amount representing from 0.01% to 15% of the total weight of the composition and preferably in an amount representing from 0.5% to 5% , in particular from 1 to 5% of the total weight of the composition.
Les compositions selon l'invention peuvent également contenir des agents de bronzage et/ou de brunissage artificiels de la peau (agents autobronzants), tels que par exemple de la dihydroxyacétone (DHA).The compositions according to the invention may also contain artificial tanning and / or browning agents for the skin (self-tanning agents), such as for example dihydroxyacetone (DHA).
Les compositions de l'invention peuvent comprendre en outre des adjuvants cosmétiques classiques notamment choisis parmi les corps gras, les solvants organiques, les épaississants, les adoucissants, les antioxydants, les opacifiants, les stabilisants, les émollients, les hydroxyacides, les agents anti-mousse, les agents hydratants, les vitamines, les parfums, les conservateurs, les tensloactifs, les charges, les séquestrants, les propulseurs, les agents alcalinisants ou acidifiants, les colorants, ou tout autre ingrédient habituellement utilisé en cosmétique, en particulier pour la fabrication de compositions antisolaires sous forme d'émulsions.The compositions of the invention may also comprise conventional cosmetic adjuvants in particular chosen from fatty substances, organic solvents, thickeners, softeners, antioxidants, opacifiers, stabilizers, emollients, hydroxy acids, anti-aging agents. foam, moisturizing agents, vitamins, perfumes, preservatives, surfactants, fillers, sequestrants, propellants, alkalizing or acidifying agents, colorants, or any other ingredient usually used in cosmetics, in particular for manufacturing of sunscreen compositions in the form of emulsions.
Les corps gras peuvent être constitués par une huile ou une cire ou leurs mélanges, et ils comprennent également les acides gras, les alcools gras et les esters d'acides gras. Les huiles peuvent être choisies parmi les huiles animales, végétales, minérales ou de synthèse et notamment parmi l'huile de vaseline, l'huile de paraffine, les huiles de silicone, volatiles ou non, les isoparaffines, les huiles fluorées et perfluorées. De même, les cires peuvent être choisies parmi les cires animales, fossiles, végétales, minérales ou de synthèse connues en soi.The fatty substances can consist of an oil or a wax or their mixtures, and they also include fatty acids, fatty alcohols and fatty acid esters. The oils can be chosen from animal, vegetable, mineral or synthetic oils and in particular from petroleum jelly oil, paraffin oil, silicone oils, volatile or not, isoparaffins, fluorinated and perfluorinated oils. Likewise, the waxes can be chosen from animal, fossil, vegetable, mineral or synthetic waxes known per se.
Parmi les solvants organiques, on peut citer les alcools et polyols inférieurs.Among the organic solvents, mention may be made of lower alcohols and polyols.
Les épaississants peuvent être choisis notamment parmi les homopolymères d'acide acrylique réticulés, les gommes de guar et celluloses modifiées ou non telles que la gomme de guar hydroxypropylée, la méthylhydroxyéthylcellulose, l'hydroxypropylméthyl cellulose ou encore l'hydroxyéthylcellulose.The thickeners can be chosen in particular from crosslinked acrylic acid homopolymers, guar gums and modified or unmodified celluloses such as hydroxypropylated guar gum, methylhydroxyethylcellulose, hydroxypropylmethyl cellulose or even hydroxyethylcellulose.
Bien entendu, l'homme de l'art veillera à choisir ce ou ces éventuels composés complémentaires et/ou leurs quantités de manière telle que les propriétés avantageuses, en particulier le niveau de photoprotection, attachées intrinsèquement à l'association binaire conforme à l'invention ne soient pas, ou substantiellement pas, altérées par la ou les adjonctions envisagées.Of course, those skilled in the art will take care to choose this or these optional additional compounds and / or their quantities in such a way that the advantageous properties, in particular the level of photoprotection, intrinsically attached to the binary association in accordance with invention are not, or not substantially, altered by the planned addition (s).
Les compositions de l'invention peuvent être préparées selon les techniques bien connues de l'homme de l'art, en particulier celles destinées à la préparation d'émulsions de type huile-dans-eau ou eau-dans-huile, ou encore des compositions anhydres.The compositions of the invention can be prepared according to techniques well known to those skilled in the art, in particular those intended for the preparation of emulsions of oil-in-water or water-in-oil type, or alternatively anhydrous compositions.
Cette composition peut se présenter en particulier sous forme d'emulsion, simple ou complexe (H/E, E/H, H/E/H ou E/H/E) telle qu'une crème, un lait, un gel ou un gel crème, de poudre, de composition solide, de pâtes souples et éventuellement être conditionnée en aérosol et se présenter sous forme de mousse ou de spray.This composition can be presented in particular in the form of a simple or complex emulsion (O / W, W / O, O / W / O or W / O / W) such as a cream, a milk, a gel or a cream gel, powder, solid composition, flexible pasta and optionally be packaged as an aerosol and be in the form of a foam or spray.
Lorsqu'il s'agit d'une emulsion, la phase aqueuse de celle-ci peut comprendre une dispersion vésiculaire non ionique préparée selon des procédés connus (Bangham, Standish and Watkins. J. Mol. Biol. 13, 238 (1965), FR2315991 et FR2416008).When it is an emulsion, the aqueous phase thereof may comprise a nonionic vesicular dispersion prepared according to known methods (Bangham, Standish and Watkins. J. Mol. Biol. 13, 238 (1965), FR2315991 and FR2416008).
La composition cosmétique de l'invention peut être utilisée comme composition protectrice de l'épiderme humain ou des cheveux contre les rayons ultraviolets, comme composition antisolaire ou comme produit de maquillage.The cosmetic composition of the invention can be used as a composition for protecting the human epidermis or the hair against ultraviolet rays, as a sunscreen composition or as a make-up product.
Lorsque la composition cosmétique selon l'invention est utilisée pour la protection de l'épiderme humain contre les rayons UV, ou comme composition antisolaire, elle peut se présenter sous forme de suspension ou de dispersion dans des solvants ou des corps gras, sous forme de dispersion vésiculaire non ionique ou encore sous forme d'emulsion, de préférence de type huile-dans-eau, telle qu'une crème ou un lait, sous forme de pommade, de gel, de gel crème, de stick, de pâtes souples, de mousse aérosol ou de spray.When the cosmetic composition according to the invention is used for the protection of the human epidermis against UV rays, or as an antisun composition, it may be in the form of a suspension or of dispersion in solvents or fatty substances, in the form of nonionic vesicular dispersion or alternatively in the form of an emulsion, preferably of the oil-in-water type, such as a cream or a milk, in the form of an ointment, gel, cream gel, stick, flexible pasta, aerosol or spray foam.
Lorsque la composition cosmétique selon l'invention est utilisée pour la protection des cheveux, elle peut se présenter sous forme de shampooing, de lotion, de gel, d'emulsion, de dispersion vésiculaire non ionique et constituer par exemple une composition à rincer, à appliquer avant ou après shampooing, avant ou après coloration ou décoloration, avant, pendant ou après permanente ou défrisage, une lotion ou un gel coiffants ou traitants, une lotion ou un gel pour le brushing ou la mise en plis, une composition de permanente ou de défrisage, de coloration ou décoloration des cheveux.When the cosmetic composition according to the invention is used for protecting the hair, it can be in the form of a shampoo, lotion, gel, emulsion, nonionic vesicular dispersion and constitute, for example, a composition to be rinsed, applying before or after shampooing, before or after coloring or bleaching, before, during or after perming or straightening, a styling or treating lotion or gel, a lotion or gel for brushing or setting, a composition of perm or hair straightening, coloring or bleaching.
Lorsque la composition est utilisée comme produit de maquillage des cils, des sourcils ou de la peau, tel que crème de traitement de l'épiderme, fond de teint, bâton de rouge à lèvres, fard à paupières, fard à joues, mascara ou ligneur encore appelé "eye liner", elle peut se présenter sous forme solide ou pâteuse, anhydre ou aqueuse, comme des émulsions huile dans eau ou eau dans huile, des dispersions vésiculaires non ioniques ou encore des suspensions.When the composition is used as an eyelash, eyebrow or skin makeup product, such as epidermis treatment cream, foundation, lipstick stick, eyeshadow, blush, mascara or liner also called "eyeliner", it can be in solid or pasty, anhydrous or aqueous form, such as oil in water or water in oil emulsions, nonionic vesicular dispersions or even suspensions.
A titre indicatif, pour les formulations antisolaires conformes à l'invention qui présentent un support de type emulsion huile-dans-eau, la phase aqueuse (comprenant notamment les filtres hydrophiles) représente généralement de 50 à 95% en poids, de préférence de 70 à 90% en poids, par rapport à l'ensemble de la formulation, la phase huileuse (comprenant notamment les filtres lipophiles) de 5 à 50% en poids, de préférence de 10 à 30% en poids, par rapport à l'ensemble de la formulation, et le ou les (co)émulsionnant(s) de 0,5 à 20% en poids, de préférence de 2 à 10% en poids, par rapport à l'ensemble de la formulation.As an indication, for the sunscreen formulations in accordance with the invention which have an oil-in-water emulsion type support, the aqueous phase (comprising in particular hydrophilic filters) generally represents from 50 to 95% by weight, preferably from 70 to 90% by weight, relative to the whole of the formulation, the oily phase (comprising in particular lipophilic filters) from 5 to 50% by weight, preferably from 10 to 30% by weight, relative to the whole of the formulation, and the emulsifier (s) from 0.5 to 20% by weight, preferably from 2 at 10% by weight, relative to the entire formulation.
L'invention a encore pour objet l'utilisation de l'association d'au moins un agent filtrant les rayonnements ultra-violets et d'un ou plusieurs agents stimulant la synthèse de la mélanine, dans une composition ou pour la préparation d'une composition filtrante bronzante.Another subject of the invention is the use of the combination of at least one agent which filters ultraviolet radiation and one or more agents stimulating the synthesis of melanin, in a composition or for the preparation of a bronzing filter composition.
L'invention a en outre pour objet un procédé de traitement cosmétique de la peau destiné à la protéger contre les effets des rayons UV tout en lui conférant un bronzage naturel consistant à appliquer sur la peau une quantité efficace d'un produit tel que défini précéderhment ou d'une composition cosmétique le comprenant.The subject of the invention is also a method of cosmetic treatment of the skin intended to protect it against the effects of UV rays while giving it a natural tan consisting in applying to the skin an effective amount of a product as defined above. or a cosmetic composition comprising it.
Les exemples et compositions suivants illustrent l'invention sans la limiter aucunement. Dans les compositions les proportions indiquées sont des pourcentages en poids.The following examples and compositions illustrate the invention without limiting it in any way. In the compositions the proportions indicated are percentages by weight.
Exemple 1 : Préparation d'un extrait de Chrysanthemum sinensis :Example 1: Preparation of an extract of Chrysanthemum sinensis:
Des feuilles de plants de Chrysanthemum sinensis cultivés sous serre sont prélevées et séchées durant 48 heures dans une étuves ventilées à une température de 45°C.Leaves of plants of Chrysanthemum sinensis grown in a greenhouse are removed and dried for 48 hours in a ventilated oven at a temperature of 45 ° C.
Les feuilles séchées sont ensuite réduites en poudre par broyage sur un broyeur à couteau du type Culatti.The dried leaves are then reduced to powder by grinding on a knife grinder of the Culatti type.
La poudre obtenue est tamisée sur une grille dont les trous ont un diamètre de 1 mm. C'est cette poudre tamisée qui est utilisée pour la préparation de l'extrait.The powder obtained is sieved on a grid whose holes have a diameter of 1 mm. It is this sifted powder that is used for the preparation of the extract.
Protocole 1 :Protocol 1:
La poudre est mélangée à un solvant d'extraction aqueux constitué par du milieu de culture cellulaire DMEM/F 12,3 : 1 vendu par la société Life Technologies, à raison d'une concentration de 5 grammes de poudre sèche pour 100 ml de solvant. Le mélange est maintenu sous agitation pendant 4 heures à température ambiante. Le mélange est alors centrifugé à 1000 tours /minute pendant 8 minutes et le surnageant est prélevé et soumis à deux cycles de centrifugations/prélèvement identiques.The powder is mixed with an aqueous extraction solvent consisting of DMEM / F cell culture medium 12.3: 1 sold by the company Life Technologies, at a concentration of 5 grams of dry powder per 100 ml of solvent . The mixture is stirred for 4 hours at room temperature. The mixture is then centrifuged at 1000 rpm for 8 minutes and the supernatant is removed and subjected to two identical centrifugation / removal cycles.
Le dernier surnageant prélevé est filtré sur filtre 0,22 μm de type Millipore en conditions aseptiques afin d'être stérilisé et conservé à une température de 4°C. jusqu'à utilisation.The last supernatant removed is filtered through a 0.22 μm Millipore type filter under aseptic conditions in order to be sterilized and stored at a temperature of 4 ° C. until use.
Protocole 2 :Protocol 2:
La poudre est mélangée à de l'eau déminéralisée stérile ayant un pH de 6,5 à raison d'une concentration de 2,5 grammes de poudre sèche pour 100 ml d'eau. Le mélange est maintenu sous agitation pendant 30 minutes à température ambiante. Le mélange est alors filtré sur membranes GFD vendues par la société Whatmann ayant une porosité de 0,7μ. Le filtrat obtenu est alors filtré sur filtre 0,22 μm de type Nalgene en conditions aseptiques afin d'être stérilisé et conservé à une température de 4°C. jusqu'à utilisation.The powder is mixed with sterile demineralized water having a pH of 6.5 at a concentration of 2.5 grams of dry powder per 100 ml of water. The mixture is stirred for 30 minutes at room temperature. The mixture is then filtered on GFD membranes sold by the company Whatmann having a porosity of 0.7 μ. The filtrate obtained is then filtered on a 0.22 μm Nalgene type filter under aseptic conditions in order to be sterilized and stored at a temperature of 4 ° C. until use.
Protocole 3 : Le protocole précédent est réalisé en remplaçant l'eau par un solvant d'extraction aqueux constitué par du milieu de culture cellulaire DMEM/F 12, 3 : 1 vendu par la société Life Technologies.Protocol 3: The previous protocol is carried out by replacing the water with an aqueous extraction solvent consisting of DMEM / F 12 cell culture medium, 3: 1 sold by the company Life Technologies.
Protocole 4 : L'extrait obtenu au protocole 2 est lyophilisé à 30°C après congélation à -20°C. La poudre obtenue est utilisé directement. Exemple 2 : Mesure de l'effet photoprotecteur et propigmentant de l'association du Mexoryl SX® (3,3'-(1,'phenylènedimethylidyne)bis(7,7dimethyi-2- oxobicyclo[2,2,1]heptane-1-methanesulfonicacid) avec soit un extrait de Burnet soit un extrait de Chrysanthemum sinensis obtenu par le protocole 2 de l'exemple 1.Protocol 4: The extract obtained in Protocol 2 is lyophilized at 30 ° C after freezing at -20 ° C. The powder obtained is used directly. EXAMPLE 2 Measurement of the Photoprotective and Propigmenting Effect of the Association of Mexoryl SX® (3.3 '- (1,' phenylenedimethylidyne) bis (7,7dimethyi-2-oxobicyclo [2,2,1] heptane-1 -methanesulfonicacid) with either an extract of Burnet or an extract of Chrysanthemum sinensis obtained by protocol 2 of Example 1.
L'effet photoprotecteur et propigmentant de l'association a été testé sur co- cultures de kératinocytes / mélanocytes humains normaux selon la méthode décrite dans le brevet FR95 06491 par évaluation de la mélanogénèse induite par les UV. Le taux de la synthèse de mélanine est évalué par l'incorporation de thiouracile marquée au C14. Il est rapporté à \a quantité de protéine .The photoprotective and propellant effect of the association was tested on co-cultures of normal human keratinocytes / melanocytes according to the method described in patent FR95 06491 by evaluation of melanogenesis induced by UV. The rate of melanin synthesis is evaluated by the incorporation of thiouracil labeled with C 14 . It is related to the amount of protein.
Les kératinocytes humains normaux (NHK) et les mélanocytes humains normaux (NHM) sont cultivés à partir de peau de prépuce. Les deux types de cellules sont amplifiés et stockés congelés. Huit jours avant le test, chacun des types cellulaires est remis en culture. Les kératinocytes sont cultivés selon la méthode décrite par Rheinwald et Green (Cell (1975) 6, 331-334) sur des cellules nourricières (fibroblastes 3T3) dans le milieu de croissance Green 7F (DMEM/F12 3:1, sérum de veau fœtal (Gibco) 10%, adenine 0,18 mM, facteur de croissance épidermique EGF 10 ng/ml, hydrocortisone 0,4μg/ml; insuline 5μg/ml, isoprotérénole 10μM, transferrine 5μg/ml, triiodothyronine, 2nM) . Les mélanocytes sont amplifiés dans le milieu M2 (Olsson, M.J. et al., Lancet (1992) 340, 981). Les milieux sont changés tous les deux jours.Normal human keratinocytes (NHK) and normal human melanocytes (NHM) are grown from foreskin skin. Both types of cells are amplified and stored frozen. Eight days before the test, each of the cell types is returned to culture. The keratinocytes are cultured according to the method described by Rheinwald and Green (Cell (1975) 6, 331-334) on feeder cells (fibroblasts 3T3) in the growth medium Green 7F (DMEM / F12 3: 1, fetal calf serum (Gibco) 10%, adenine 0.18 mM, epidermal growth factor EGF 10 ng / ml, hydrocortisone 0.4μg / ml; insulin 5μg / ml, isoproterenole 10μM, transferrin 5μg / ml, triiodothyronine, 2nM). The melanocytes are amplified in the M2 medium (Olsson, M.J. et al., Lancet (1992) 340, 981). The media are changed every two days.
3 jours avant le test, 250 000 kératinocytes humains normaux et 80 000 mélanocytes humains normaux sont mélangés et ensemencés par puits de plaques de 24 puits (type Costar) et cultivés trois jours dans le milieu de croissance des kératinocytes (Green 7F) sans rouge de phénol.. Pendant les quatre jours suivants, le milieu de culture est remplacé quotidiennement par le milieu UV (DMEM/F12 3:1 sans rouge de phénol, sérum de veau défini 2% (HyClone), EGF 10 ng/ml, facteur de croissance fibroblastique de type β (βFGF) 10 ng/ml) L'induction de la pigmentation par les UV est réalisée par simulation solaire (SSR) à l'aide d'un simulateur solaire Oriel Xénon de 1000 Watts comprenant un filtre dichroïque 280-400nm (Oriel, modèle 81035) et un filtre WG 320 de marque Schott possédant une longueur d'onde de coupure de 311nm (correspondant à une épaisseur d'environ 1.5mm).3 days before the test, 250,000 normal human keratinocytes and 80,000 normal human melanocytes are mixed and seeded with wells of 24-well plates (Costar type) and cultured three days in keratinocyte growth medium (Green 7F) without red of phenol .. During the following four days, the culture medium is replaced daily by the UV medium (DMEM / F12 3: 1 without phenol red, calf serum defined 2% (HyClone), EGF 10 ng / ml, factor β-type fibroblastic growth (βFGF) 10 ng / ml) The UV pigmentation induction is carried out by solar simulation (SSR) using a 1000 Watts Oriel Xenon solar simulator including a 280-400nm dichroic filter (Oriel, model 81035) and a WG 320 filter of Schott brand with a cut-off wavelength of 311nm (corresponding to a thickness of about 1.5mm).
Les cultures cellulaires sont irradiées 1 fois par jour pendant 4 jours dans une solution tampon phosphate (PBS).The cell cultures are irradiated once a day for 4 days in a phosphate buffer solution (PBS).
Les molécules propigmentantes sont mises en contact avec les cellules dans le PBS pendant l'irradiation et ajoutées au milieu de culture (milieu UV) après l'irradiation.The propigmenting molecules are brought into contact with the cells in PBS during the irradiation and added to the culture medium (UV medium) after the irradiation.
L'extrait de Burnet est testé à 0,005%. Il est préparé dans une solution mère àBurnet extract is tested at 0.005%. It is prepared in a stock solution at
0.5% dans un solvant (Dimethylsulfoxide DMSO) qui est ajouté au millième dans le PBS et dans le milieu UV. La concentration finale du solvant dans le milieu de culture est donc 1/1000.0.5% in a solvent (Dimethylsulfoxide DMSO) which is added to the thousandth in PBS and in the UV medium. The final concentration of the solvent in the culture medium is therefore 1/1000.
L'extrait de Chrysanthemum sinensis obtenu selon les protocoles n" 2 + 4 est testé à 1 %.The extract of Chrysanthemum sinensis obtained according to protocols No. 2 + 4 is tested at 1%.
La tyrosine qui sert de contrôle positif est testée à 500 μM.Tyrosine, which serves as a positive control, is tested at 500 μM.
Le Mexoryl SX® est testé à 8 %Mexoryl SX® is tested at 8%
INGREDIENTSINGREDIENTS
QUANTITEAMOUNT
EAU 60WATER 60
TEREPHTHALYLIDENE DICAMPHOR SULFONIC ACID 8TEREPHTHALYLIDENE DICAMPHOR SULFONIC ACID 8
PROPYLENE GLYCOL 8PROPYLENE GLYCOL 8
GLYCERINE 7GLYCERINE 7
HUILE de SILICONE 8SILICONE OIL 8
C12-15 ALKYL BENZOATE 2C12-15 ALKYL BENZOATE 2
ALCOOL STEARYLIQUE 1,5STEARYL ALCOHOL 1,5
PVP/EICOSENE COPOLYMER 1PVP / EICOSENE COPOLYMER 1
SODIUM STEAROYL GLUTAMATE 1 ACIDE STEARIQUE 1,5SODIUM STEAROYL GLUTAMATE 1 STEARIC ACID 1.5
PEG-100 STEARATE 0,75PEG-100 STEARATE 0.75
GLYCERYL STEARATE 0,75GLYCERYL STEARATE 0.75
CARBOMER 0,3CARBOMER 0.3
HYDROXYPROPYL METHYLCELLULOSE 0,1HYDROXYPROPYL METHYLCELLULOSE 0.1
TRIETHA OLAMINE QS pH 7TRIETHA OLAMINE QS pH 7
CONSERVATEUR QSCONSERVATIVE QS
PARFUM QSQS PERFUME
Après chaque exposition aux UV, les formulations contant le filtre solaire sont appliquées à raison de 1,4 mg/cm2 sur une lame de quartz sur laquelle se trouve une bande de Transpore® selon une méthode dérivée de celle utilisée pour la détermination des indices de protection solaire in vitro décrite par Diffey et Robspn ( J Soc Cosmet Chemists (1989) 300, 230-235). L'ensemble est disposé au dessus des co-cultures pendant la durée de l'irradiation.After each exposure to UV, the formulations containing the solar filter are applied at the rate of 1.4 mg / cm 2 on a quartz slide on which there is a strip of Transpore® according to a method derived from that used for determining the indices. in vitro sunscreen described by Diffey and Robspn (J Soc Cosmet Chemists (1989) 300, 230-235). The assembly is placed above the co-cultures for the duration of the irradiation.
Après irradiation, les cellules sont incubées dans le milieu UV contenant 1 μCi/ml de thiouracile marquée au C14.After irradiation, the cells are incubated in UV medium containing 1 μCi / ml of thiouracil labeled with C 14 .
Mesure de la mélanogénèse : Les témoins suivants sont réalisés :Measurement of melanogenesis: The following controls are carried out:
- culture contrôle : Pas de produit testé- control culture: No product tested
- culture contrôle solvant : le solvant des produits testés est ajouté- solvent control culture: the solvent of the tested products is added
- témoin positif de stimulation de la mélanogénèse : tyrosine 500μM ;- positive control for stimulation of melanogenesis: tyrosine 500 μM;
24 heures après la dernière irradiation UV, les cellules sont rincées en tampon phosphate. Les protéines sont précipitées à l'aide d'acide trichloracétique (TCA) à 5% et lavées afin d'éliminer la radioactivité libre. Les cellules sont lysées pendant la nuit à 40°C à l'aide d'une solution de protéinase K à 100 μg/ml dans du tampon Tris HCI-triton-EDTA. 5 μl d'extrait total sont prélevés et transférés dans une plaque 96 puits (Wallac) pour le dosage des protéines qui est effectué avec le kit MicroBCA *Protein Assay Reagent (Pierce).24 hours after the last UV irradiation, the cells are rinsed in phosphate buffer. The proteins are precipitated using 5% trichloroacetic acid (TCA) and washed in order to remove the free radioactivity. The cells are lysed overnight at 40 ° C. using a proteinase K solution at 100 μg / ml in Tris HCl-triton-EDTA buffer. 5 μl of total extract are taken and transferred to a 96-well plate (Wallac) for the protein assay which is carried out with the MicroBCA * Protein Assay Reagent kit (Pierce).
Le reste de l'extrait, soit 950 μl, est filtré sur filtre DEAE Filtermat. Après rinçage, le filtre recouvert du scintillant solide « Meltilex » est transféré dans une plaque. La radioactivité est comptée à l'aide du compteur Wallac . Les résultats sont exprimés en pourcentage du contrôle témoin, ou du contrôle solvant si le produit est solubilisé dans un autre solvant que l'eau, selon les formules:The rest of the extract, i.e. 950 μl, is filtered on a DEAE Filtermat filter. After rinsing, the filter covered with the solid glitter "Meltilex" is transferred to a plate. Radioactivity is counted using the Wallac counter. The results are expressed as a percentage of the control control, or of the solvent control if the product is dissolved in a solvent other than water, according to the formulas:
(14CP / qté protéine P ) - (14CT / qté protéine T )(14CP / qty protein P) - (14CT / qty protein T)
X 100X 100
(14CT / qté protéine T )(14CT / qty protein T)
et (14CP / mg protéine P ) - (14CS / mg protéine S )and (14CP / mg protein P) - (14CS / mg protein S)
X 100X 100
(14CS / qté protéine S)(14CS / qty protein S)
dans lesquelles: 4CP est la moyenne des désintégrations par minute (dpm) thiouracile 14C sur 3 puits similaires traités par un produit (P) ;in which: 4 CP is the average of the disintegrations per minute (dpm) thiouracil 14 C on 3 similar wells treated with a product (P);
Qté protéine P est la moyenne des quantités de protéines dans les puits correspondants (en milligramme),Qty protein P is the average amount of protein in the corresponding wells (in milligrams),
14CT est la moyenne des dpm thiouracile 14 C sur 3 puits similaires témoin (T) ; . Qté protéine T est la moyenne des quantités de protéines dans les puits correspondants ( en milligramme), 14 CT is the average of 14 C thiouracil dpm over 3 similar control wells (T); . Qty protein T is the average amount of protein in the corresponding wells (in milligrams),
14CS est la moyenne des dpm thiouracile 14 C sur 3 puits similaires contrôles solvant (S) ; qté protéine S est la moyenne des quantités de protéines dans les puits correspondants (en milligramme). Résultats : % de variation de la synthèse de mélanine par rapport au contrôle (cellules non traitées par le produit et non irradiées) 14 CS is the average of the thiouracil dpm 14 C over 3 similar wells solvent controls (S); protein S quantity is the average of the quantities of protein in the corresponding wells (in milligrams). Results:% variation in melanin synthesis compared to control (cells not treated with the product and not irradiated)
Produitsproducts
Irradiation seule (SSR) 222Irradiation only (SSR) 222
Irradiation seule + solvant 251Irradiation only + solvent 251
Tyrosine 500 μM 40Tyrosine 500 μM 40
Extrait de Burnet à 0,005% (solvant) 1100.005% Burnet Extract (solvent) 110
Extrait de Chrysanthemum sinensis 1 % 500Chrysanthemum sinensis extract 1% 500
SSR + Mexoryl SX® 8% 15SSR + Mexoryl SX® 8% 15
SSR+ solvant + Mexoryl SX® 8% 36SSR + solvent + Mexoryl SX® 8% 36
SSR + Tyrosine 500 μM 382SSR + Tyrosine 500 μM 382
SSR + Extrait de Burnet à 0,005% (solvant) 466SSR + 0.005% Burnet Extract (solvent) 466
SSR + Extrait de Chrysanthemum sinensis 1 % 588SSR + Chrysanthemum sinensis extract 1% 588
SSR + Tyrosine 500 μM + Mexoryl SX® 8% 74SSR + Tyrosine 500 μM + Mexoryl SX® 8% 74
SSR + Extrait de Burnet à 0,005% + Mexoryl SX® 8% (solvant) 460SSR + 0.005% Burnet Extract + Mexoryl SX® 8% (solvent) 460
SSR + Extrait de Chrysanthemum sinensis 1% + Mexoryl SX® 8% 428SSR + Chrysanthemum sinensis extract 1% + Mexoryl SX® 8% 428
A = 14CthioU/qté protéine (%/contrôle)A = 14 CthioU / protein qty (% / control)
Les variations de synthèse de mélanine mesurée dans les différentes conditions donnent lieu au classement suivant :The variations in melanin synthesis measured under the different conditions give rise to the following classification:
SSR + MSX < SSR + MSX + propigmentant < ou = SSR + propigmentantSSR + MSX <SSR + MSX + propigmentant <or = SSR + propigmentant
Conclusions :Conclusions:
Ces résultats montrent, qu'en association avec un filtre en forte concentration, un produit propigmentant permet la restauration du brunissement (synthèse de mélanine).These results show that, in combination with a filter in high concentration, a propigmenting product allows the restoration of browning (synthesis of melanin).
Exemple 3 : Composition bronzante et filtrante à appliquer sur la peau contenant un extrait de Burnet à 1 % %EXAMPLE 3 Bronzing and Filtering Composition to Apply to the Skin Containing a 1% Burnet Extract %
Eau 60 terephthalylidene dicamphor sulfonic acid 8 propyleneglycol 8 glycérine 7 huile de silicone 8Water 60 terephthalylidene dicamphor sulfonic acid 8 propylene glycol 8 glycerin 7 silicone oil 8
Alcool 12-15 alkyl benzoate 2 stearyl 1,5 pvp/eicosene copolymer 1 sodium stéaroyl glutamate 1 acide stéarique 1 ,5 stéarate de peg-100 0,75 stéarate de glycéryl 0,75 carbomer 0,3 hydroxypropyl methylcellulose 0,1 triéthanolamine qs pH 7Alcohol 12-15 alkyl benzoate 2 stearyl 1.5 pvp / eicosene copolymer 1 sodium stearoyl glutamate 1 stearic acid 1, 5 peg-100 stearate 0.75 glyceryl stearate 0.75 carbomer 0.3 hydroxypropyl methylcellulose 0.1 triethanolamine qs pH 7
Conservateur qsConservative qs
Parfum qsPerfume qs
On ajoute à cette composition un extrait sec de racine et de rhizome de Sanguisorba officinalis qui peut notamment être obtenu sous forme de poudre auprès de MARUZEN PHARMACEUTICALS CO., LTD (Burnet Extract Powder), de telle sorte que sa concentration dans le produit fini est de 1 %.A dry extract of the root and rhizome of Sanguisorba officinalis is added to this composition, which can in particular be obtained in powder form from MARUZEN PHARMACEUTICALS CO., LTD (Burnet Extract Powder), so that its concentration in the finished product is from 1 %.
Exemple 4 : Composition bronzante et filtrante à appliquer sur la peau contenant chrysanthemum sinensis à 1%Example 4: Bronzing and filtering composition to be applied to the skin containing chrysanthemum sinensis at 1%
% Eau 60 terephthalylidene dicamphor sulfonic acid 8 propyleneglycol 8 glycérine 7 huile de silicone 8% Water 60 terephthalylidene dicamphor sulfonic acid 8 propyleneglycol 8 glycerin 7 silicone oil 8
Alcool 12-15 alkyl benzoate 2 stearyl 1 ,5 pvp/eicosene copolymer 1 sodium stéaroyl glutamate 1 acide stéarique 1 ,5 stéarate de peg-100 0,75 stéarate de glycéryl 0,75 carbomer 0,3 hydroxypropyl methylcellulose 0,1 triéthanolamine qs pH 7Alcohol 12-15 alkyl benzoate 2 stearyl 1, 5 pvp / eicosene copolymer 1 sodium stearoyl glutamate 1 stearic acid 1, 5 peg-100 stearate 0.75 glyceryl stearate 0.75 carbomer 0.3 hydroxypropyl methylcellulose 0.1 triethanolamine qs pH 7
Conservateur qs Parfum qsPreservative qs Perfume qs
On ajoute à cette composition un extrait chrysamthemum sinensis obtenu selon FR 2768343, de telle sorte que sa concentration dans le produit fini est de 1 %. A chrysamthemum sinensis extract obtained according to FR 2768343 is added to this composition, so that its concentration in the finished product is 1%.

Claims

REVENDICATIONS
1. : Produit composé par au moins l'association d'au moins un agent filtrant les rayonnements ultra-violets et d'au moins un agent stimulant la synthèse de la mélanine.1.: Product composed by at least the combination of at least one agent filtering ultraviolet radiation and at least one agent stimulating the synthesis of melanin.
2. : Produit selon la revendication 1, caractérisé en ce que l'agent filtrant les rayonnements ultraviolets est choisi parmi les filtres organiques et/ou les filtres minéraux.2.: Product according to claim 1, characterized in that the filtering agent for ultraviolet radiation is chosen from organic filters and / or mineral filters.
3. : Produit selon l'une quelconque des revendications 1 ou 2, caractérisé en ce que l'agent filtrant les rayonnements ultra-violets est un filtre organique choisi parmi les dérivés cinnamiques, les dérivés salicyliques, les dérivés du camphre, les dérivés de triazine, les dérivés de la benzophénone, les dérivés du dibenzoylméthane, les dérivés de β,β-diphénylacrylate, les dérivés de l'acide p- aminobenzoïque, les polymères filtres et silicones filtres.3.: Product according to any one of claims 1 or 2, characterized in that the agent filtering ultraviolet radiation is an organic filter chosen from cinnamic derivatives, salicylic derivatives, camphor derivatives, derivatives of triazine, benzophenone derivatives, dibenzoylmethane derivatives, β, β-diphenylacrylate derivatives, p-aminobenzoic acid derivatives, filter polymers and filter silicones.
4. : Produit selon l'une quelconque des revendications 1 ou 2, caractérisé en ce que l'agent filtrant les rayonnements ultra-violets est un filtre minéral choisi parmi les pigments ou nanopigments d'oxydes métalliques enrobés ou non comme par exemple des nanopigments d'oxyde de titane (amorphe ou cristallisé sous forme rutile et/ou anatase), de fer, de zinc, de zirconium ou de cérium.4. Product according to any one of claims 1 or 2, characterized in that the agent filtering ultraviolet radiation is a mineral filter chosen from pigments or nanopigments of metallic oxides coated or not, such as nanopigments for example titanium oxide (amorphous or crystallized in rutile form and / or anatase), iron, zinc, zirconium or cerium.
5. : Produit selon l'une quelconque des revendications 1 à 4, caractérisé en ce que l'agent filtrant les rayonnements ultra-violets est un filtre solaire actif dans l'UV-A et/ou l'UV-B,5.: Product according to any one of claims 1 to 4, characterized in that the agent filtering ultraviolet radiation is a sun filter active in UV-A and / or UV-B,
6. : Produit selon l'une quelconque des revendications 1 à 5, caractérisé en ce que l'agent filtrant les rayonnements ultra-violets est choisi parmi l'acide p- aminobenzoïque, le p-aminobenzoate oxyéthyléné (25mol), le p-diméthylaminobenzoate de 2-éthylhexyle, le p-aminobenzoate d'éthyle N-oxypropyléné le p-aminobenzoate de glycérol, le salicylate d'homomenthyle, le salicylate de 2-éthylhexyle, le salicylate de triéthanolamine, le salicylate de 4-isopropylbenzyle, le 4-ter-butyl-4'-méthoxy-dibenzoylméthane, le 4-isopropyl-dibenzoylméthane, - l'anthranilate de menthyle, le 2-éthylhexyl-2-cyano-3,3'-diphénylacrylate, réthyl-2-cyano-3,3'-diphénylacrylate, l'acide 2-phényl benzimidazole 5-sulfonique et ses sels, le 3-(4'-triméthylammonium)-benzylidèn-bornan-2-on-méthylsulfate, le 2-hydroxy-4-méthoxybenzophénone, le 2-hydroxy-4-méthoxybenzophénone-5-sulfonate, le 2,4-dihydroxybenzophénone, le 2,2',4,4'-tétrahydroxybenzophénone, le 2,2'-dihydroxy-4,4'diméthoxybenzophénone, le 2-hydroxy-4-n-octoxybenzophénone, le 2-hydroxy-4-méthoxy-4'-méthylbenzophénone, l'acide α-(2-oxobom-3-ylidène)-tolyl-4-sulfonique et ses sels le 3-(4'-sulfo)benzylidèn-bornan-2-one et ses sels,6.: Product according to any one of claims 1 to 5, characterized in that the filtering agent for ultraviolet radiation is chosen from p-aminobenzoic acid, oxyethylenated p-aminobenzoate (25mol), p- 2-ethylhexyl dimethylaminobenzoate, N-oxypropylenated ethyl p-aminobenzoate glycerol p-aminobenzoate, homomenthyl salicylate, 2-ethylhexyl salicylate, triethanolamine salicylate, 4-isopropylbenzyl salicylate, 4-ter-butyl-4 '-methoxy-dibenzoylmethane, 4-isopropyl-dibenzoylmethane, - menthyl anthranilate, 2-ethylhexyl-2-cyano-3,3'-diphenylacrylate, rethyl-2-cyano-3,3'-diphenylacrylate, l 2-phenyl benzimidazole 5-sulfonic acid and its salts, 3- (4'-trimethylammonium) -benzylidèn-bornan-2-on-methylsulfate, 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxybenzophenone -5-sulfonate, 2,4-dihydroxybenzophenone, 2,2 ', 4,4'-tetrahydroxybenzophenone, 2,2'-dihydroxy-4,4'dimethoxybenzophenone, 2-hydroxy-4-n-octoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, α- (2-oxobom-3-ylidene) -tolyl-4-sulfonic acid and its salts 3- (4'-sulfo) benzyliden-bornan- 2-one and its salts,
Ie 3-(4'méthylbenzylidène)-d,l-camphre, le 3-benzylidène-d,l-camphre, l'acide benzène 1 ,4-di(3-méthylidène-10-camphosulfonique) et ses sels, l'acide urocanique, la 2,4,6-tris-[ p-(2'-éthylhexyl-1 '-oxycarbonyl)anilino]-1 ,3,5-triazine,Ie 3- (4'methylbenzylidene) -d, l-camphor, 3-benzylidene-d, l-camphor, benzene acid 1, 4-di (3-methylidene-10-camphosulfonic) and its salts, urocanic acid, 2,4,6-tris- [p- (2'-ethylhexyl-1 '-oxycarbonyl) anilino] -1, 3,5-triazine,
2-[(p-(tertiobutylamido)anilino]-4,6-bis-[(p-(2'-éthylhexyl-1'-oxycarbonyl)anilino]-2 - [(p- (tert-butylamido) anilino] -4,6-bis - [(p- (2'-ethylhexyl-1'-oxycarbonyl) anilino] -
1,3,5-triazine, la 2,4-bis {[4-2-éthyl-hexyloxy)]-2-hydroxy]-phenyl}-6-(4-méthoxy-phenyl)-1 ,3,5- triazine ; le polymère de N-(2 et 4)-[(2-oxoborn-3-ylidèn)méthyl] benzylj-acrylamide, l'acide 4,4-bis-benzimidazolyl-phénylèn-3,3',5,5'-tétrasulfonique et ses sels le 2,2'-méthylèn-bis-[6-(2H-benzotriazol-2-yl)-4-(1 ,1 ,3,3-tétraméthylbutyl)phénol]. les polyorganosiloxanes à fonction malonate.1,3,5-triazine, 2,4-bis {[4-2-ethyl-hexyloxy)] - 2-hydroxy] -phenyl} -6- (4-methoxy-phenyl) -1, 3,5- triazine; the polymer of N- (2 and 4) - [(2-oxoborn-3-ylidèn) methyl] benzylj-acrylamide, 4,4-bis-benzimidazolyl-phenylen-3,3 ', 5,5'-tetrasulfonic acid and its salts 2,2'-methylen-bis- [6- (2H-benzotriazol-2-yl) - 4- (1, 1, 3,3-tetramethylbutyl) phenol]. polyorganosiloxanes with a malonate function.
7. : Produit selon l'une quelconque des revendications 1 à 6, caractérisé en ce que l'agent filtrant les rayonnements ultra-violets est en une quantité représentant de 0,1% à 25% du poids total de la composition.7.: Product according to any one of claims 1 to 6, characterized in that the agent filtering ultraviolet radiation is in an amount representing from 0.1% to 25% of the total weight of the composition.
8. : Produit selon l'une quelconque des revendications 1 à 7, caractérisé en ce que l'agent filtrant les rayonnements ultra-violets est en une quantité représentant de8.: Product according to any one of claims 1 to 7, characterized in that the agent filtering ultraviolet radiation is in an amount representing
0,5% à 10% du poids total de la composition.0.5% to 10% of the total weight of the composition.
9. : Produit selon l'une quelconque des revendications 1 à 8, caractérisé en ce que l'agent stimulant la synthèse de la mélanine est choisi parmi les analogues de substrats de la tyrosinase tels que la tyrosine, la L-dopa ou la L- dihydroxylphenylalanine, les activateurs de l'activité ou de l'expression de la tyrosinase tels que la forskoline, les bases xanthiques (théophylline, caféine), les peptides pro-opiomélanocortiques (ACTH, alpha-MSH ou autres agonistes de des récepteurs MC1), les diacylglycérols, les diols aliphatiques ou cycliques, les psoralenes, les prostaglandines et analogues, les activateurs de la protéine kinase G NO/cGMP dépendante, ou des activateurs de transfert des mélanosomes vers les kératinocytes tels que les serine protéases ou d'agonistes des récepteurs PAR-2.9.: Product according to any one of claims 1 to 8, characterized in that the agent stimulating the synthesis of melanin is chosen from analogues of substrates of tyrosinase such as tyrosine, L-dopa or L - dihydroxylphenylalanine, activators of the activity or expression of tyrosinase such as forskolin, xanthic bases (theophylline, caffeine), pro-opiomelanocortic peptides (ACTH, alpha-MSH or other agonists of MC1 receptors) , diacylglycerols, aliphatic or cyclic diols, psoralens, prostaglandins and the like, activators of protein kinase G NO / cGMP dependent, or activators of transfer of melanosomes to keratinocytes such as serine proteases or agonists of PAR-2 receptors.
10. : Produit selon l'une quelconque des revendications 1 à 9, caractérisé en ce que l'agent stimulant la synthèse de la mélanine est un extrait de Burnet (Sanguisorba officinalis) ou encore un extrait d'au moins un végétal du genre Chrysanthemum.10.: Product according to any one of claims 1 to 9, characterized in that the agent stimulating the synthesis of melanin is an extract of Burnet (Sanguisorba officinalis) or also an extract of at least one plant of the genus Chrysanthemum .
11. : Produit selon l'une quelconque des revendications 1 à 10, caractérisé en ce que l'agent stimulant la synthèse de la mélanine est un extrait d'au moins un végétal de l'espèce Chrysanthemum sinensis. 11.: Product according to any one of claims 1 to 10, characterized in that the agent stimulating the synthesis of melanin is an extract of at least one plant of the species Chrysanthemum sinensis.
12. : Produit selon l'une quelconque des revendications 1 à 11, caractérisé en ce que l'agent stimulant la synthèse de la mélanine est en une quantité représentant de 0,01% à 15% du poids total de la composition.12.: Product according to any one of claims 1 to 11, characterized in that the agent stimulating the synthesis of melanin is in an amount representing from 0.01% to 15% of the total weight of the composition.
13. : Produit selon l'une quelconque des revendications 1 à 12, caractérisé en ce que l'agent stimulant la synthèse de la mélanine est en une quantité représentant de 1% à 5% du poids total de la composition.13.: Product according to any one of claims 1 to 12, characterized in that the agent stimulating the synthesis of melanin is in an amount representing from 1% to 5% of the total weight of the composition.
14. : Composition comprenant au moins un produit tel que défini dans l'une quelconque des revendicationsl à 13.14.: Composition comprising at least one product as defined in any one of claimsl to 13.
15. : Utilisation dans une composition ou pour la préparation d'une composition d'au moins un produit tel que défini dans l'une quelconque des revendicationsl à 13.15.: Use in a composition or for the preparation of a composition of at least one product as defined in any one of claimsl to 13.
16. : Procédé de traitement cosmétique de la peau destiné à la protéger contre les effets des rayons UV tout en lui conférant un bronzage naturel consistant à appliquer sur la peau une quantité efficace d'un produit ou d'une composition cosmétique selon l'une des revendications 1 à 15. 16.: A method of cosmetic treatment of the skin intended to protect it against the effects of UV rays while giving it a natural tan consisting in applying to the skin an effective amount of a cosmetic product or composition according to one of claims 1 to 15.
EP02726261A 2001-04-09 2002-04-09 Filtering suntan product Withdrawn EP1385472A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0104808A FR2823112B1 (en) 2001-04-09 2001-04-09 TANNING AND FILTERING PRODUCT
FR0104808 2001-04-09
PCT/FR2002/001238 WO2002080878A2 (en) 2001-04-09 2002-04-09 Filtering suntan product

Publications (1)

Publication Number Publication Date
EP1385472A2 true EP1385472A2 (en) 2004-02-04

Family

ID=8862112

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02726261A Withdrawn EP1385472A2 (en) 2001-04-09 2002-04-09 Filtering suntan product

Country Status (5)

Country Link
US (1) US20040170580A1 (en)
EP (1) EP1385472A2 (en)
JP (1) JP3870164B2 (en)
FR (1) FR2823112B1 (en)
WO (1) WO2002080878A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US7381403B2 (en) 2003-04-14 2008-06-03 L'oreal Finely divided photoprotective oil-in-water emulsions comprising 4,4-diarylbutadiene UV-A sunscreens
FR2853537B1 (en) * 2003-04-14 2006-06-23 Oreal OIL-IN-WATER FINE PHOTOPROTECTIVE EMULSION, METHOD FOR MANUFACTURING THE SAME, AND USE IN THE COSMETIC AND DERMATOLOGICAL FIELDS
AU2005277203A1 (en) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
CN101076348A (en) * 2004-10-08 2007-11-21 克里纽沃药物有限公司 Compositions and methods for inducing melanogenesis in a subject
NZ572334A (en) * 2004-12-22 2010-02-26 Omj Ireland Ltd Phototherapy compositions comprising 8-methoxypsoralen and 2-ethylhexyl p-dimethylaminobenzoate
KR100879215B1 (en) 2007-01-12 2009-01-16 이권재 Inorganic UV blocker
ES2585847T3 (en) * 2010-06-30 2016-10-10 Galderma Research & Development Use of an alpha adrenergic receptor agonist to prevent or treat a skin tumor
CA2810746A1 (en) 2010-06-30 2012-01-05 Galderma Research & Development Method for preventing or treating skin tumor
DE102010042147A1 (en) * 2010-10-07 2012-04-12 Beiersdorf Ag Preservative-free sunscreen
FR2970868B1 (en) * 2011-01-31 2023-10-27 Sederma Sa EXTRACT OF PLANT ORIGIN, COMPOSITION CONTAINING IT, METHOD OF OBTAINING BY PLANT CULTURE AND USES IN THE COSMETIC, PHARMACEUTICAL AND COSMECEUTICAL FIELDS
EP2724709A1 (en) 2012-10-24 2014-04-30 Unilever N.V. A sunscreen composition containing ester salts of L-DOPA
JP6086706B2 (en) * 2012-11-14 2017-03-01 ポーラ化成工業株式会社 Skin external composition having high UV absorption effect
DE102013208880A1 (en) * 2013-05-14 2014-11-20 Beiersdorf Ag Stabilized preparations containing ascorbic acid and mixtures of sodium stearoylglutamate and / or cetylstearylsulfate in combination with glyceryl stearate
KR101326556B1 (en) * 2013-08-02 2013-11-07 주식회사 더마랩 Cosmetic composition for ultraviolet-proof containing the extract of sanguisorba officinalis and v. linariaefolia
CN114533580A (en) * 2022-03-09 2022-05-27 水羊化妆品制造有限公司 Ultraviolet screening agent and preparation method and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2409751A1 (en) * 1977-11-29 1979-06-22 Thorel Jean Noel Sun tan compsn. giving rapid bronzing - contg. 5-methoxy psoralen, lanolin, and UV filter cpd.
CH642537A5 (en) * 1980-01-25 1984-04-30 Uni Chemie Ag Cosmetic sunscreen product
CH671514A5 (en) * 1986-12-03 1989-09-15 Induchem Ag
FR2622103B1 (en) * 1987-10-22 1990-02-09 Thorel Jean Noel NEW INSECTIFUGAL TANNING DERMATOLOGICAL COMPOSITIONS
CH675967A5 (en) * 1987-12-09 1990-11-30 Induchem Ag
GB8901837D0 (en) * 1989-01-27 1989-03-15 Beecham Group Plc Novel compositions
FR2654935B1 (en) * 1989-11-28 1994-07-01 Lvmh Rech USE OF XANTHINES, WHICH MAY BE INCORPORATED IN LIPOSOMES, TO PROMOTE PIGMENTATION OF THE SKIN OR HAIR.
DE19653736C2 (en) * 1996-12-12 2002-11-21 Lancaster Group Gmbh Cosmetic preparation with added peptide
ATE226064T1 (en) * 1997-09-12 2002-11-15 Procter & Gamble SKIN CLEANSING AND CONDITIONING ITEMS FOR SKIN AND HAIR
FR2768343B1 (en) * 1997-09-18 2000-03-10 Oreal USE OF AT LEAST ONE EXTRACT OF AT LEAST ONE PLANT OF THE GENUS CHRYSANTHEMUM FOR PROMOTING PIGMENTATION OF THE SKIN AND / OR HAIR
FR2782920B1 (en) * 1998-09-07 2000-10-06 Oreal USE OF AT LEAST ONE ROSACEA EXTRACT OF THE GENUS SANGUISORBA OFFICINALIS TO PROMOTE PIGMENTATION OF THE SKIN AND / OR HAIR
FR2797585B1 (en) * 1999-08-19 2001-10-26 Jean Jacques Goupil COMPOSITION FOR TOPICAL ADMINISTRATION COMPRISING 5-METHOXYPSORALENE
US20030044478A1 (en) * 2001-08-15 2003-03-06 Epstein Howard A. Burnet extract

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02080878A2 *

Also Published As

Publication number Publication date
FR2823112A1 (en) 2002-10-11
JP3870164B2 (en) 2007-01-17
JP2004525161A (en) 2004-08-19
FR2823112B1 (en) 2004-03-05
US20040170580A1 (en) 2004-09-02
WO2002080878A3 (en) 2002-11-21
WO2002080878A2 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
CA2657703C (en) Use of a rice protein hydrolysate as pigmenting active principle
EP0685225B1 (en) Cosmetic sunscreening compositions and uses
EP0685222B1 (en) Cosmetic sunscreening compositions and uses
EP1385472A2 (en) Filtering suntan product
EP1195156A1 (en) Use of an ericaceae extract in skin-ageing treatment
EP1244464B1 (en) Extract of dedifferentiated cells from a plant belonging to the genus leontopodium and compositions containing same
EP3980124B1 (en) Extract of moringa peregrina seed cake, method for obtaining same and use thereof in cosmetic or nutricosmetic compositions
FR2817747A1 (en) USE OF AT LEAST ONE SAPOGENIN, OR A NATURAL EXTRACT CONTAINING SAME, TO PREVENT THE SIGNS OF SKIN AGING
FR2812544A1 (en) Treatment of cutaneous aging symptoms, such as wrinkles, comprises topical or oral administration of Salvia genus plant extracts with collagenase expression inhibiting activity
AU745485B2 (en) Compositions for artificially colouring the skin and uses thereof
FR2932086A1 (en) ANTI-AGE COSMETIC CARE METHOD BY STIMULATING THE EXPRESSION OF SURVIVAL
FR2961402A1 (en) COMPOSITIONS CONTAINING ARABINOXYLO-OLIGOSACCHARIDES AND USES THEREOF
FR2650952A1 (en) COSMETIC OR PHARMACEUTICAL COMPOSITION, IN PARTICULAR DERMATOLOGICAL, CONTAINING A COLEUS EXTRACT AND PROCESS FOR PREPARING THE SAME
EP0865271A1 (en) Stabilised sunscreen compositions
FR2665637A1 (en) Cosmetic or pharmaceutical composition containing an extract of Coleus esquirolii, Coleus scutellarioides, Coleus xanthanthus or a mixture thereof
EP1150649B1 (en) Cosmetic compositions for photoprotection of the skin and/or hair containing a benzotriazole silicone derivative and a triazine bis-resorcinyl derivative
EP0766510B1 (en) Use of a commiphora mukul extract as a pigmenting agent
EP1331923A2 (en) Use of the association of at least an plant extract of genus rosmarinus and of at least a carotenoid
FR3143372A1 (en) NEUROCOSMETIC COMPOSITION TO PREVENT THE EFFECTS OF STRESS
FR2834454A1 (en) Composition for artificial skin tanning comprises a sorghum extract
FR2831434A1 (en) Use of an extract of Plectranthus, especially Plectranthus argentatus, as a skin colorant in cosmetic artificial skin tanning compositions
FR2834455A1 (en) Composition for artificial skin tanning comprises a mono- or polycarbonyl self-tanning agent and a sorghum extract

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031110

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20080730

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090210